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OBJECTIVES OF THE STUDY: 
To evaluate the prevalence of metabolic syndrome using IDF criteria in premature 
coronary artery disease proven by coronary angiogram. 
METHODS: 
       Patients under  45yrs of age who were diagnosed to have acute coronary syndrome proven 
by  coronary angiogram will be included in this study. The eligible subjects are explained about 
the study and after getting consent  will be evaluated for metabolic syndrome parameters(using 
IDF criteria) and subjected for thorough clinical examination. All the collected data will be 
analyzed and the important findings of the study will be highlighted. 
RESULTS: 
1.  Patients with metabolic syndrome had an average HDL-cholesterol level of about 32.36, 
whereas in non-MS group the average value was 36.78,with p value of <0.05 which is 
statistically significant 
2.  The average triglyceride value in MS group was 179.14,whereas in non-MS group it was 
115.86,with p value of <0.01 which is statistically significant. 
3.  Fasting blood glucose was high in 43 patients (64.17%) in MS group, whereas it was high 
only in 9 patients (39.13%) of the non-MS group with the p-value of <0.05 which is 
statistically significant.  
4.  44 patients (65.67%) of the MS-group and only 6 patients (26.08%) of the non-MS group 
had elevated blood pressure of more than 130/85mmHg, with the p-value of <0.01 which 
is statistically significant. 
5.  Average WC of patients in MS group and non-MS group were 95.64 and 
87.23respectively. The p-value came as <0.001 which is statistically very significant. 
6.  Patients (46.26%) with MS were found to have pre-existing  hypertension compared to 3 
(13.04%) in non-MS patients. The p-value obtained was <0.01, which is statistically 
significant. 
7. 10 Patients (14.92%) in the MS group and 2 patients(8.69%) in the non-MS group had 
history suggestive of CAD in the family. 
8.  42 patients (62.68%) in MS group and 15patients (65.21%) in non-MS group were 
smokers with p-value of 0.825(not significant) 
9.  32 patients (47.76%) in MS group and 13 patients(56.52%) in non MS group were 
alcoholic. p-value obtained was 0.468 which is statistically not significant. 
10.  36 (53.7%) out of 67 patients in MS group presented with ST elevation MI, whereas it is 
18(78.26%) out of 23 in NON MS with the p value of 0.03 which is statistically 
significant (this may be attributed to occlusion of the vessel by emboli in N-MS group 
but whereas in MS atherosclerotic occlusion of the vessel is more common than embolic). 
11.  23 (34.32%) out of 67 patients in MS group and 11(47.82%) out of 23 in NON MS group 
had LV dysfunction with the p value of 0.24, which is statistically not significant. 
CONCLUSION 
• In our study, 90 cases of acute MI aged ≤ 45 were studied for metabolic syndrome using 
IDF criteria. MS was diagnosed in 67 of 90 cases studied. 
• Waist circumference was followed by Diabetes mellitus /Systemic hypertension/ elevated 
BP / hypertriglyceridemia/ elevated FBS and decrease in fasting HDL arranged in the 
order of prevalence in the study group which was statistically significant. 
• Among the 67 patients, 14 met all criteria for MS, 24subjects had 4 and 29 subjects had 3 
of 5 MS criteria, With WC ≥ 80 for females and ≥ 90 for males being a definite criterion. 
• The prevalence of alcohol, whether a smoker ,history of CAD in the family, dyslipidemia 
, and  vessel involvement – SVD/DVD/TVD were same for both MS and non MS group. 
• Thus it is obvious that MS predominates over other conventional criteria or scores in 
estimating the risk of developing MI and related complications and its prevalence in our 
study population is 74.4% which is very significant.  
• Though people living in low income countries like India have lower risk factor for CVD, 
compared with high income countries, the rate of death due to CVD is highest in low 
income countries. This is because there is better control of risk factor due to frequent use 
of proven drugs to reduce the risk of deaths. 
• Thus determinants like easy and timely access to health care and medicine, diagnosis of 
risk factor and treatment / control and greater awareness play an important role in 
preventing death.  Hence the two means to counter the risk factors and decrease the 
mortality are health promotion and health care. 
• Health promotion component is to raise awareness and risk reduction. This is better done 
by identifying at risk individuals by the presence of MS component in this group and 
providing health care facilities for early detection and effective treatment in order to 
prevent cardiovascular disease morbidity and mortality. 
• From the study it is clear that IDF consensus definition for MS suits Indians best for 
identifying high risk individuals. Hence we recommend its use to help prevent CVD 
morbidity and mortality in younger individuals in whom it is difficult to estimate CVD 
risk. 
• As the risk factors have an increasing trend in India so does the mortality. The 
cardiovascular crisis is waiting to worsen unless we improve the health care system.  
• Hence  risk factor modification, regular physical activity and healthy diet among young 
patients should be emphasised for primary prevention of CAD. 
• The concept of metabolic syndrome is very important as it provides simple  and 
comprehensive information to the public.The medical professional should assess for 
presence of all the MS parameters whenever necessary. 
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INTRODUCTION 
Coronary artery disease affecting younger individuals has reached 
enormous proportions. There is of no doubt that it will become a major 
public health problem in future unless we concentrate on reversible cause 
and prevention through research studies1.Most common cause for 
myocardial infarction is coronary artery thrombosis, secondary to 
atherosclerosis2.Metabolic syndrome (MS) refers to a constellation of 
complex inter related risk factors for cardiovascular disease and diabetes 
which appears to directly promote the development of atherosclerotic 
cardiovascular disease3.The syndrome X (MS) represents a combination 
of multiple risk factors like central adiposity, hypertension, dysglycemia  
due to development of insulin resistance, lipid abnormalities like elevated 
triglycerides, low HDL (high density lipoprotein) cholesterol levels, pro-
thrombotic and pro-inflammatory state in the same person which occur 
together more frequently than predicted by chance alone4 
The prevalence of metabolic syndrome in Indian varies from region 
to region. A recent review on insulin resistance syndrome showed a rapid 
increase in its development among Indians5.Studies on patients with 
metabolic syndrome showed around six fold raise in cardiovascular 
mortality than compared to those without metabolic syndrome6.  
2
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Though the association between MS and CVD is certain, the 
level of associated risk is not clearly defined due to difference in 
proposed definitions7 
Traditional risk factors constitutes around half the risk of 
development of first myocardial insult, especially in Asian Indian 
population. The burden of cardiovascular disease is likely to increase 
in the incoming years with significant impact on the society8.  
For allocation of research and health resources it is essential for 
us to understand the dimensions of this metabolic syndrome as it can 
cause serious morbidity.  
However fewer studies reported on the existence of MS among 
native Indian population based on epidemiological studies and almost 
only very few studies are available on its prevalence in younger 
individuals with significant cardiovascular morbidity. This is important 
especially in country like India with a large number of diabetic 
patients9.   
Early intervention in patients with metabolic syndrome with 
intensive approach to lifestyle and behaviour modification in the form 
of diet, exercises and drugs may prevent the development of 
cardiovascular disease in the future. 
3
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In our study we have used International Diabetes Federation 
criteria (which have race and ethnic specific waist circumference cut-
off points) in order to know MS prevalence in premature coronary 
artery disease patients proved by angiogram. This may help in 
providing direction for future research and health intervention. 
Patients with MS are at increased risk of developing 
cardiovascular disease and are also associated with increased mortality 
and morbidity, which makes a clear understanding of this problem, is 
vital for allocation of resources and health care. Traditional risk factors 
together constitute approximately half of the chance of developing a 
first episode of MI, especially among Asian Indian population. As a 
result, both incidence and prevalence of cardiovascular disease is likely 
to increase in the incoming years with significant socio-economic 
consequences. 
However regarding the prevalence of MS as a whole in the 
native Indian population only few studies are available based on 
epidemiological studies and almost no studies are available on its 
prevalence in younger individuals with significant cardiovascular 
morbidity. 
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Early intervention to the MS patients by means of intensive 
lifestyle and behaviour modification in the form of diet, exercises and 
drugs may prevent the future development of cardiovascular disease 
like myocardial infarction. 
To know the actual burden of MS in the community this study 
has been undertaken to find the exact distribution of MS in those with 
atherosclerotic coronary vascular disease proven by angiogram through 
the definition framed by International Diabetes Federation as this 
appears to be ideal in Indian setup. This may help in providing 
direction for future research. 
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AIM  
Aim: To estimate the prevalence of metabolic syndrome in patient with 
definitive evidence of premature coronary artery disease. 
Objective:  
To assess prevalence of metabolic syndrome by IDF criteria in 
angiogram proven premature coronary artery disease patients. 
Methods: 
        Type of study        :  Cross-sectional study 
        Study population:  90 patients with premature ACS proven by  
    CAG 
        Period of study     :   2014 March to 2014 August 
        Inclusion criteria: 
1. Coronary artery disease proven by coronary angiogram                     
( STEMI / NSTEMI  /  UA) 
2. Age ≤ 45 years. 
Exclusion criteria: 
1. Patients who did not undergo coronary angiogram. 
2. Age >45 years. Age < 18 years 
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REVIEW OF LITERATURE 
The concept of metabolic syndrome was initially put forth by 
Kylin in 1920, who was a physician from Sweden. He described MS as 
combination of hyperglycemia, hypertension, and gout10.  
 In the year 1947, Vague gave importance to upper body obesity 
as it was the phenotype he found most commonly associated with type 
2 diabetes mellitus and cardio vascular disease11.   
In the year 1988 Reaven proposed the concept of Syndrome X 
that included resistance to insulin mediated glucose uptake, 
hyperglycemia, hyper-insulinemia, high blood pressure, 
hypertriglyceridemia, an increased VLDL cholesterol, and a decreased 
HDL cholesterol levels (high density lipoprotein). It was during this 
period hypertension, diabetes and cardio vascular disease drew much 
attention12 
Till this period there were no specific criteria for diagnosing 
syndrome X. Obesity or visceral obesity was not included in any of the 
criteria described previously. Later, Lemieux proposed that 
hypertriglyceridemia and visceral obesity be considered as a principle 
component of MS13, 14.  
7
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The WHO in 1998 suggested a specific definition of metabolic 
syndrome which was improved in due course of time after various 
research studies and analyse by many organizations and professional 
bodies. 
After crossing various stages of improvisation we now describe 
MS as a confluence of many classical risk factors for cardiovascular 
disease such as central obesity, increased blood glucose, elevated blood 
pressure, hypertriglyceridemia and low HDL-cholesterol levels. In the 
analysis even after excluding diabetes patients, MS patients were found to 
have had more than 2 fold raise in adverse cardiovascular disease 
events15, 16, 17.
Though middle aged and eldery individuals are more prone to 
develop CAD, studies showed that there is an increasing evidence of its 
occurrence in young individuals, resulting in premature death and 
disability18, 19, 20.
Acute coronary syndrome (ACS) in young patients differs from 
that in older individuals in terms of risk profile and mortality21. 
Presence of MS in an individual reflects an increased chance of 
developing atherosclerotic vascular disease and thereby it will be helpful 
in identifying high cardiovascular disease risk individuals. In a cross-
8
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sectional study it was found that more and more number of adults (>1/3) 
and children were found to have MS according to the proposed MS 
diagnostic criteria, and its distribution in patient with coronary artery 
disease seems increasing proportionately. But there are not many studies 
available on CAD patients less than 45 years with regard to MS 
prevalence22,23,24,25,26.
The DECODE study says that, there is an increasing evidence 
regarding patient with low score for cardiovascular disease risk and MS 
have increased chance of developing fatal cardiovascular disease events 
than those without MS27.
Epidemiological research has identified risk factors that increase 
the likelihood of coronary heart disease events. Management of risk 
factors can improve coronary endothelial function, stop the progression of 
atherosclerosis, prevent disruption and thrombosis of vulnerable 
atherosclerotic plaque and reduce coronary heart disease morbidity and 
mortality. When risk factors co-exist, they multiply the risk of coronary 
heart disease several fold.  
A recent Bethesda conference proposed a classification scheme 
according to the strength of evidence that risk factor intervention 
favorably affects outcome. It is difficult to find too many risk factors in 
young patients who developed coronary artery disease. MS more 
9
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commonly present in these patients. This should be practiced even in 
those subjects at low risk of developing cardiovascular disease. The 
recognition of MS will definitely be important in diagnosing patient with 
high risk of developing cardiovascular disease more so than estimated by 
other conventional cardiovascular risk scores. 
METABOLIC SYNDROME (MS) 
Obesity, especially abdominal obesity, is associated with insulin 
resistance on utilization of fatty acid and glucose at the peripheries which 
results in development of diabetes. This resistance to insulin along with 
adipocyte cytokines, hyper-insulinemia and hyperglycaemia may lead to 
an abnormal lipid profile, hypertension, vascular inflammation and 
vascular endothelial dysfunction, that will lead on to atherosclerotic 
cardiovascular disease28,29,30,31.
In the past MS has been called by different names- the obesity 
dyslipidemia syndrome, New world syndrome, Multiple syndrome, IR 
syndrome, syndrome X, the deadly quartet 32  
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Table.1   Various terminologies used to describe MS18 
• Atherothrombogenic Syndrome 
• Beer-Belly Syndrome 
• Cardiovascular disease syndrome 
• Chronic cardiovascular risk factor clustering syndrome 
• Deadly quartet 
• DysMETS 
• IR syndrome 
• Metabolic cardiovascular syndrome 
• METS 
• Multiple syndrome 
• Multiple METS 
• PluriMETS 
• Reaven’s syndrome 
• Syndrome X 
• New world syndrome 
Genetic predisposition, body fat distribution and lack of exercise, 
will affect the likelihood of development of diabetes and CVD in obese 
subjects. So each of its individual component has to be identified 
correctly and treated effectively to reduce adverse outcome related to 
diabetes mellitus and CVD33,34 
11
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DEFINITION  
There are many definitions for the metabolic syndrome. It 
represents the clustering of risk factors for diabetes and cardiovascular 
disease. These risk factors comprise glucose intolerance, hypertension, 
hypertriglyceridemia, low levels of HDL cholesterol and central obesity. 
Despite its growing prevalence worldwide there is still a lack of 
uniformity in accepted definitions and controversy regarding the 
pathogenesis of metabolic syndrome. Thus it remains an evolving concept 
with different working groups defining varied criteria for the condition.  
The various criteria proposed by different professional bodies 
include those developed by the WHO35, which used WHR to measure 
central obesity; the European Group for the Study of Insulin Resistance37 
which is a modification of WHO, used insulin resistance; this was 
followed by the NCEP ATP III  36. The used WC instead of WHR for 
quantifying central obesity. The confusions which developed while 
establishing parameters to diagnose MS with lack of consensus on fixing 
cut-offs for WC led to the development of IDF (International Diabetes 
Federation) 38 and the modified ATP III definition39.  
Several other metabolic abnormalities have also been found to be 
linked with this syndrome namely hyperuricemia, disorders of 
12
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haemostasis, microalbuminuria and elevated levels of proinsulin and 
leptin, elevated levels of PAL-1 factor VII fibrinogen and Vwf.  
Coexistence of these factors is labelled metabolic syndrome. The 
clustering together of all these risk factors tend to accelerate the 
development of atherosclerosis and increases the risk for cardiovascular 
morbidity and mortality. The presence of metabolic syndrome confers a 
2-fold increase in risk of major CVD events and 5-fold increase in risk 
for type 2 DM. The metabolic syndrome has also been identified as 
precursor state of non-alcoholic fatty liver disease, chronic kidney disease 
and chronic lung disease. Knowledge of these abnormalities has several 
therapeutic implications. 
The various definitions of the metabolic syndrome are as follows. 
The National Cholesterol Education Program (NCEP/ATP III) is the most 
widely used39. 
WHO DEFINITION   
In 1999, WHO proposed a definition for MS. According to this 
presence of IGT or DM, and or resistance to insulin with any two or more 
than two of the following criteria defines MS, which includes, 
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1. Increased arterial pressure ≥140/90 mmHg 
2. Raised plasma triglycerides (≥150mg/dl) and / or low HDL-C 
(<39mg/dl) 
3. Abdominal obesity with WHR more than 0.9 and 0.85 in men and 
women or BMI>30kilogram/meter square. 
4. Presence of micro-albumin in urine of ≥ 20µg/min or albumin 
creatinine ratio of ≥ 30/mg/gm creatinine. 
EUROPEAN GROUP FOR STUDY OF INSULIN RESISTANCE    
DEFINITION 
The EGIR definition of MS was a modified version of WHO which 
used IR in the place of MS. As per EGIR to diagnose IR plasma insulin 
should be high i.e. greater than the 75 percentile, together with any two of 
the following parameters  
1. Abdominal adiposity with WC ≥94cms and ≥80 cms in men and  
women. 
2. High blood pressure, more than or equal to 140/90 mmHg or on 
any anti-hypertensive drugs for systemic hypertension. 
3. Hypertriglyceridemia (≥150mg/dl) and /or low HDL-cholesterol 
levels (<39mg/dl) in both the sexes  
4.  IGT/IFG, but should not be a diabetic. 
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NCEP ATP III DEFINITION 
NCEP ATP III developed guidelines based on factors which 
influence high risk of developing cardiovascular disease40. This was 
modified by AHA and NHLBI in the year 200541,42
It includes the following  
• Lowered FBG cut-off to 100 mg/dl, 
• Diabetics were included in the criteria 
• To make the process simple in diagnosing MS, NCEP ATP III 
proposed a definition which used WC in place of WHR for 
quantifying central obesity 
• Patients on lipid lowering and anti-hypertensive drugs were 
included in the criteria 
• As per this patient is considered to have MS if at least any of the 
following 3 criteria is present: 
• Waist circumference  ≥ 102 cms and  ≥ 88 cm for men and women  
• Hyper triglyceridemia:  ≥ 150 mg/dl or on lipid lowering drugs for 
hypertriglyceridemia 
• Low HDL –C: <40 mg/dl and <50 mg/dl for for men and women 
or treatment for the same. 
15
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• High systolic blood pressure ≥130 mmHg or diastolic ≥ 85mmHg 
or receiving treatment for high blood pressure 
• High fasting glucose ≥110 mg/dl or receiving treatment for 
elevated blood glucose. 
According to NCEP ATP III abdominal adiposity is considered more 
important than generalised adiposity and WC was included and body 
mass index from the definition. The term IRS was proposed as they 
believed IR is not a principal component for developing MS.  
For quantification of abdominal obesity NCEP ATP III used WC and 
omitted WHR as suggested by WHO. They put low HDL and 
hypertriglyceridemia as two discrete parameter in the criteria because 
each has a major role in development of CVD and diabetes. They 
excluded parameters like microalbuminuria from the criteria which made 
diagnosis of MS easy. They also reduced the cut-off points for 
hypertension and HDL cholesterol levels. Though NCEP considered MS 
as a pro inflammatory state, they did not include this in the criteria for 
defining MS. Previously there was always a difficulty in applying all the 
above criteria in different ethnic groups and races due to significant 
difference in the WC among them (including Asians). 
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IDF-DEFINITION  
IDF proposed MS definition based on ethnic and race specific WC 
cut-off and updated their MS criteria in the year 2006 43. According to the 
IDF, patient is considered to have MS if any three of the following 
criteria is present with abdominal adiposity as a principle component 
(with ethnic and race specific cut off for WC)  
The race and gender specific waist circumference cut-offs 
suggested are as follows:  
TABLE 2: WAIST CIRCUMFERENCE IN GENDER AND RACE SPECIFIC 
GROUPS 
Country          WC cut-off 
Europeans  
Americans [continue using NCEP 
ATP III values (102cm for M & 
88cm for F) ] 
       for  Males in 
cm  
     for Females in 
cm  
 
≥  94 
 
 
≥ 80 
 Asians especially South Asians 
based on a Asian-Indian & Chinese, 
population 
≥90 ≥80 
China  ≥90 ≥80 
Japan ≥90 ≥80 
 South-Americans and Central 
America  
Use south Asian WC data 
 Africans  Use European WC data  
 Mediterranean and Middle east  Use European WC data  
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CRITERIA: 
• Hypertriglyceridemia  ≥ 150 mg/dl or on lipid lowering drugs for 
the same. 
• Decreased HDL levels  <40  mg/dl and <50  mg/dl in men and 
women, or on drugs for this same abnormality 
• Increased Systolic Blood Pressure ≥ 130, and diastolic Blood 
Pressure  ≥ 85, or on anti-hypertensive for the same (SHT). 
• FBS ≥ 100 mg/dl, or known case of diabetes mellitus and on drugs 
for the same. 
The ADA and European association for diabetic study suggested 
that, to tag a person having MS does not confers any additional risk 
than contribution by any of its individual parameter. 
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COMPARISON 
TABLE 3: THE CURRENT DEFINITIONS APPLIED BY 
THREEDIFFERENT ORGANISATIONS 
                               
WHO 1999 
                         
NCEP / ATP III 
2005 
                             
IDF 2005 
S.No Criteria 
required 
1st/5th with >2 other 
criteria 
Any 3 criteria 2nd+ any 2 
other criteria 
1. Insulin 
resistance 
Yes - - 
2. Obesity WHR : 
 male  >0.9          
female > 0.85, body 
mass index >30  
 
WC :  
Male >102 
female >88 
Ethnicity 
specific 
3. Lipid TG>150mg or 
HDL<35(M),<39(F) 
TG>150mg or 
HDL<50(M),<40(F) 
TG>150mg or 
HDL<50(M),<
40(F) 
4. Blood 
pressure 
>140/90mmHg >130/85mmHg or 
on therapy 
>130/85mmH
g or on 
therapy 
5. Glucose T2DM                
IGT                    
IFG 
Fasting >100mg/dl 
or DM 
Fasting 
>100mg/dl or 
DM 
6. Other Microalbuminuria  - - 
19
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From the NHNES survey database started in 1999 regarding 
prevalence of MS in American adults 39% had MS by IDF criteria,33.5% 
had MS by NCEP ATP III criteria44.And there is an overlap in 93 percent 
of subjects making it difficult to diagnose MS in those patients. When the 
same was applied to a city dwelling population it was found that more 
than 18% of subjects were found to have MS than compared to those 
diagnosed by NCEP ATP III45.From an epidemiological study on urban 
and rural Chennai population (CURES) MS was diagnosed in 23% of 
patients studied via WHO criteria, 18% with NCEP ATP III criteria and 
25.8% with the help of IDF criteria but only 224 patients were diagnosed 
to have had MS when all three criteria were applied46.  
When levels of inflammatory markers like CRP, PAI-1, and   IL-6 
are elevated ,they result  in high risk of developing CVD and diabetes 47-
53
. But the association between the metabolic syndrome and elevated CRP 
levels was not demonstrated in a study on phenotype patterns and its 
relation with the MS 54. Hence whether to treat this pro-inflammatory 
state in the background of metabolic syndrome is not 
known.AHA/CDC guidelines suggested that C-reactive protein levels can 
be tested based on clinical judgment and should be optional and not 
recommended routinely55. 
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CONTRIBUTION OF THE INDIVIDUAL RISK FACTORS TO 
THE GENESIS OF CV RISK IN METABOLIC SYNDROME 
OBESITY 
Overweight and obesity are increasing in our population. No group 
is exempt from developing obesity; it occurs in all age groups and all 
genders. In Asian–Indians, subcutaneous fat depots and abdominal 
obesity predispose to metabolic syndrome and insulin resistance. 
Abdominal obesity is characterised by increased WC and WHR. However 
in Asian-Indians the waist circumference may not be that large but 
abdominal obesity is prominent. Enlarged adipocytes are related to 
development of IR and predisposes to diabetes mellitus contributing to 
CVD risk in patients with metabolic syndrome56. 
ROLE OF ADIPOCYTES IN THE DEVELOPMENT OF METABOLIC 
SYNDROME 
       Visceral fat is metabolically more active when compared to 
subcutaneous fat in the aspects of insulin sensitivity. Visceral adipose 
tissue will have histology and metabolism different from that of 
subcutaneous adipose tissue. It has adipocytes resistant to insulin and 
inflammatory cell infiltrates. Two hormones secreted by visceral adipose 
tissue appear to play a key role in generation of metabolic syndrome: 
TNFα and adiponectin. Expression of TNFα is increased during weight 
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gain and reduced during weight loss. TNFα and adiponectin have 
opposite action in the process of activating of NF- κB. This activated 
TNFα causes oxidative stress, which worsens the pathological process 
ending in oxidation of LDL and other lipid abnormalities, intolerance to 
glucose and resistance to insulin, elevated blood pressure, and damage to 
the endothelium and finally leads to the development of atherosclerosis. 
Endothelial damage and dysfunction is secondary to the NF- κB 
activation which when activated further results in recruitment of 
inflammatory cytokines and other molecules like VCAM, ICAM 
(adhesion molecules) which further aggravates the disease process. 
Further activation of  NF- κB by increased levels of FFA, high glucose, 
and insulin levels in blood secondary to insulin resistance will alter 
natural metabolic process  resulting in development of clinical 
manifestations of MS. 
A phenotype with increased body fat with comparatively low BMI, 
decreased lean body mass especially in lower limbs , high body fat /body 
mass index ratio, increased WHR, sub scapular Vs triceps skin fold 
thickness  and increased intramyocellular lipids has become more 
prevalent in Asians especially Indians57. 
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Figure 1: Pathogenesis of MS 
Tumour Necrosis Factor-α 
and 
Adiponectin in adipose tissue. 
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Increased body weight has a major role in the development of MS. 
The NHANES III Survey, it was found that the prevalence of MS in those 
who were of normal weight was 5 percent, it was 22 percent in 
overweight, and 60 percent in the obese58, 59.  
A 2.25 kg or more weight gain over 16 years increases the chance 
of getting MS 21 to 44 percent60.  
  A large waist circumference alone can predict future risk of 
developing metabolic syndrome. It can identify about 46 percent of 
subjects who are likely to get MS in the near future especially within five 
years61 making it necessary to implement primary prevention strategies 
by improving physical fitness and by reducing weight, targeting 
obesity62,63 
Other factors — Factors like age, race, and weight, postmenopausal 
status, high carbohydrate diet, smoking, decreased physical inactivity, 
poor cardio respiratory fitness, soft drink consumption, drugs like 
clozapine all have their influence on development of metabolic 
syndrome64,65,66.Genetic factors/family history of obesity accounts for 
around 50 percent chance of developing metabolic syndrome traits in 
offspring67 . 
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HISTORY OF CAD 
Though symptoms related to angina pectoris and myocardial 
infarction were seen from ancient times it came to light only in late 16th 
century which gave better understanding and knowledge on this disease. 
The first study on heart in the world perceiving the relation between the 
arrhythmia and loss of consciousness with an account of ischemia and 
myocardial infarction was put forth as a text in practica medicinalis by 
Bishop Thomas of Wroclaw (1297-1378)100. 
 In the 18th century better knowledge of coronary vascular anatomy 
lead to the real discovery of   IHD and MI by a physician who announced 
his observation in 1768. He was an English physician William Heberden 
(1710-1801till the 19th century it was named Heberden’s disease after 
him. 
Followed by Heberden, it was Ludwig Hekben, a pathologist in 
1879 who confirmed that it was the thrombotic occlusion of the 
coronaries that was the primary pathology responsible for the 
development of MI102. 
It was in the year 1910 that clinicians from Russia suspected 
possible acute MI in 5 patients103. In 1912 James Herrick insisted on strict 
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bed rest for treating patients with MI104. In 1919 he described the role of 
ECG in diagnosis of MI105. 
Better understanding of this disease in terms of patho-physiology 
and management was established in the year 1960 after many research 
studies. With a  goal to study the life style of individuals residing in 
Framingham, USA to identify “Factors of Risk in the development of 
coronary artery disease”, and to know the influence of various factor in 
the development of heart disease the Framingham Heart Study was 
established by NHLBI in the year 1948 106. 
From the study they found that 
1. Patient with high arterial blood pressure and or increased level of 
cholesterol in blood are at increased risk of developing heart 
disease. 
2. Higher incidence of myocardial infarction in women but the 
presentation was later when compared to men. 
Studying the risk factors causing atherosclerotic cardiovascular 
disease NHLBI suggested life style and behaviour modifications, 
and educated clinicians for better control of the disease in terms of 
mortality and morbidity107. Knowing the mechanism causing 
underlying pathology, NHLBI implemented prevention and control 
strategy by educating clinicians.  
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 Many clinical studies were undertaken after understanding the 
concepts of this disease targeting control of blood pressure and 
cholesterol level through drugs by collaborating with various 
professional bodies in the community 
CORONARY ATHEROSCLEROSIS 
From various genetic and molecular studies it was clear that 
atherosclerosis develops secondary to long term inflammation of arteries 
which over a period of time forms an atheromatous plaque. The oxidative 
stress which acts as a trigger factor may be secondary to smoking, SHT, 
obesity etc. All these risk factors contributes to the alteration in 
endothelial permeability thereby causing endothelial injury. Exposure of 
sub endothelial collagen recruits lipid containing macrophages and other 
inflammatory cell which together with proliferation of endothelial smooth 
muscle cell and deposition of a  fibrous collagen results in the formation 
of fibrous cap on to the growing atheromatous plaque. This atheromatous 
plaque when ruptured result in platelet aggregation at the local site plus 
release of other inflammatory mediators from platelets causing local 
vasospasm and activation of extrinsic coagulation cascade-forming 
complete occlusion of affected coronary vessel134. 
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 When the occlusion is chronic and incomplete it results in stable 
angina, unstable angina when it is complete but temporary and MI when 
the occlusion is permanent129. 
LDL cholesterol in plasma normally enters in to the cell through 
receptor mediated endocytosis which is clatherin mediated. When there is 
a defect in any of these the level of LDL will start rising in the blood. 
LDL has the capacity to take cholesterol to the peripheries and its level in 
blood is controlled by three different mechanisms. 
1. Clatherin mediated engulfment of LDL receptor when it gets 
attached to the cholesterol molecule on the cell surface 
2. Through LDL receptor recycling on the cell surface  
3. Through negative regulation of receptor (feedback inhibition) 
The  LDL receptor was discovered by Goldstein and Brawn for which 
they received Nobel Prize in the year 1985138.  This led to the discovery 
of statins by Akirra Endo which acts by inhibiting the enzyme HMG-CoA 
reductase 137.  
Statins inhibits the enzyme HMG-CoA reductase resulting in 
decreased cholesterol synthesis (de novo) inside the body thus decreases 
the chance of developing MI135,136.  
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Treatment with statins definitely prevent risk of getting MI in the 
future and improves survival rate but will not completely eliminate the 
development of CVD risk141, 142. There is always an inverse relation 
existing between HDL and development of atherosclerosis. This is 
because it contains large quantity of phospholipids which acts as a 
cholesterol acceptor and carries unlcassified cholesterol from peripheries 
to the liver there by preventing formation of atherosclerosis. It also has 
anti-inflammatory properties143. 
The drug nitric oxide which helps MI patient relieve symptoms by 
causing coronary vasodilatation was discovered by Fruchgot, Ignaro and 
Murrad for which they were awarded Nobel Prize in the year 1998130-133.  
FIGURE 2: ANTI THROMBOTIC PROPERTIES OF HDL
 
ABCA 1-ATP binding cassette protein A1; ICAM 1- intercellular adhesion molecule 
1; HDL-M medium HDL particles; HDL-S small HDL particles 
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PREMATURE CAD 
Coronary artery disease (CAD) can affect any age group, but its 
distribution in the younger age group is difficult to establish as most 
patients present with atypical symptoms. Many studies have defined 
young patients with coronary artery disease using age limit between 40 to 
45 years as the cut-off. 
Only limited data are available regarding myocardial infarction 
frequency in younger individuals. It was 12.9 per 1000 in men between 
the age of 30 - 34 years and 5.2 per 1000 in women between the age of 35 
- 45 years from the analysis done by Framingham Heart Study68 . 
In other studies, the incidence of myocardial infarctions was found 
to be 4 to 10 percent in the age group of ≤ 40 or 45 years69, 70, 71. 
Though coronary heart disease is not very common in young 
individuals it has devastating effect on their lives. Myocardial infarction 
in young and older individuals may not be similar and differ in the 
aspects of clinical presentation, risk factor profile and prognosis. 
Factors like cigarette smoking, family history, lipid abnormalities, 
diabetes, hypertension, obesity all contribute to the development of CAD. 
Among these cigarette smoking constitutes the most modifiable and very 
common risk factor prevalent in the age group of < 45 years72-78. 
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Both genetic and environmental factors influence the evolution of 
CAD in young patients with a positive family history. In the offspring of  
young CAD patients the factors which probably accounts for the 
evolution of premature CAD are increased glucose, insulin and 
cholesterol levels in blood, excessive body weight. In a study done by 
Gaeta et al and Bao et al it was found that an increased incidence (62%)  
of a positive family history of coronary artery disease in young patients 
was noted in the report of 811 patients. Increased carotid intimal media 
thickening and endothelial dysfunction were more commonly seen in the 
offspring of patient with premature coronary artery disease79, 80. 
In a study carried out by Malmberg et al it was found that high 
triglyceride level and low level of high density lipoprotein were more 
prevalent in younger individuals. Though prevalence of 
hypercholesterolemia is similar in both younger and older age group it is 
hypertriglyceridemia which became the most common lipid abnormality 
inyoung  patients with myocardial infarction as it presents with an 
intolerance to glucose and increased levels of small, atherogenic LDL 
(low density lipoprotein) particles in blood which results in development 
of atherosclerosis81. 
 
 
31

DIABETES AND HYPERTENSION  
 Most young patients have problems with metabolism of glucose. 
This is very important because impaired glucose tolerance has higher risk 
for coronary artery disease in patients without overt diabetes. On the 
other hand diabetes and hypertension seem to be less common in younger 
age groups]. 
 In a study done by Mc Gill HC et al it was obvious that obesity is 
the prime factor responsible for development of atherosclerosis of 
coronary artery, but this is more commonly seen in young men than 
compared to women. LAD and RCA are prone to develop atherosclerotic 
lesion in young men with increased body mass index82.  
Framingham Heart Study reported that around 22 % of middle 
aged men and 14% of middle-aged women with obesity had coronary 
artery disease83 
 Mansouri et al and Chang et al found that contraceptive  usage 
especially when combined with cigarette smoking, smoking marijuana, 
cocaine usage, factor-V Leiden mutation, all contribute to the 
development of coronary artery disease in young patients86-89 
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CLINICAL PRESENTATION  
Most young patients do not have angina during initial 
presentation 90. These were documented angiographically in a series of 
two hundred patients91. Young patients when compared to older 
individuals are more prone to develop acute coronary syndrome and less 
chances of developing stable angina. 
Diagnosis of acute coronary syndrome is made depending on high 
levels of cardiac biomarkers with presence of one or more of the 
following signs and symptoms which include 
                     1. Symptoms of ischemia   
                     2. Pathological q waves in electrocardiogram or elevation or     
depression of ST segment. 
Differential diagnosis in young patients who presents with signs 
and symptoms of ACS should include myocarditis. Myocarditis should be 
suspected in all young patients who presents with ACS signs and 
symptoms but normal coronary arteries proven by coronary          
angiogram92, 93. 
NON-ST ELEVATION MI 
These patients with non-ST elevation (non-Q wave) MI or unstable 
angina) are initially stabilized using medical treatment, followed by 
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revascularisation after early coronary angiography. These patients can be 
risk stratified based on exercise stress test. 
Wolfe MW et al did a study on MI patients with age less than 35 
years and re that exercise testing in asymptomatic young patients after 
myocardial infarction helps in identifying individuals coming under 
minimal risk category. In this study almost 19 subjects had minimal 
lesion in angiography done for assessing prognosis and each of them 
underwent exercise stress testing in which most of them reached up to 
stage four75. 
It is recommended that early coronary angiography is indicated 
only for those young patients with features suggestive of high risk 
category i.e. multiple risk factors or ischemia that is recurrent. 
COMMON ANGIOGRAPHIC FINDINGS IN YOUNGER 
INDIVIDUALS 
Young and older individuals not only differ in their clinical 
presentation but also in their angiographic findings. This was reported in 
the CASS trial that compared findings from a group of young men and 
women who underwent angiography (who presented with features of MI) 
with that of the older individuals. This was considered as one of the 
largest reported angiographic findings in younger individuals. Most 
34

young patients showed higher incidence of normal coronary angiogram, 
minimal luminal irregularity, they are more prone to develop single 
vessel disease 93. The inference of the study was  
1. Normal coronary angiogram were commonly seen in young patients 
(especially young women)  
2. Single vessel disease was more common than triple vessel disease, 
3. Left anterior descending artery was more commonly affected in 
younger individuals94. 
There is another entity called spontaneous coronary artery dissection. 
This spontaneous coronary dissection though rare should be considered in 
younger patients who present with features of acute coronary artery 
syndrome (especially those below 50 years of age). This is important 
because women are more prone for spontaneous coronary artery 
dissection especially in the peripartum period. 
MANAGEMENT OF ACUTE MI  
Management is mainly based on whether it is an ST-elevation or 
non-ST elevation MI.  Reperfusion with the help of primary percutaneous 
intervention or thrombolysis and revascularization is the ideal form of 
treatment in younger subjects presenting with ST-elevation MI. 
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Studies showed better outcome with primary percutaneous intervention 
than thrombolysis (GUSTO-IIb trial)95. 
PERCUTANEOUS CORONARY INTERVENTION 
In a study carried out by Mehan et al regarding the outcome of  
patients who underwent angiogram and percutaneous interventions the 
ten year event free and survival overall was 58% and 96% in the age 
group of less than 40 years i.e. good outcome97, 98. 
Restenosis and disease progression can be prevented by stenting of 
coronary arteries, particularly with drug-eluting stents and anti-platelet 
therapy and with lipid lowering drugs. 
CORONARY BYPASS SURGERY   
In a study carried out by Vedder et al regarding revascularisation 
procedure done on CAD patients and the outcome in such patients, he 
found that the it was better tolerated in younger than older individuals 
because of better physical condition and tendency to withstand 
anaesthesia and had better survival rate i.e. 93% and 81%, 72 percent and 
57 percent after 5 and 10 years post surgery. Factors like number of 
vessels involved, ventricular function, smoking, coronary artery disease 
in family influence the outcome99. 
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The patency of the graft was better with mammary artery than 
compared with saphenous vein graft i.e. it was 93% with mammary and 
56% with saphenous vein graft. Arterial grafts were preferred over 
venous graft because of good patency. 
PROGNOSIS AFTER MI  
  Young patients with acute coronary syndrome are potential 
candidates to develop adverse outcome in terms of prognosis, but severe 
coronary artery disease was uncommon and had documented good 
prognosis both on short and long term basis96.But mortality in hospital 
was zero to four percent less than older individuals. 
LONG-TERM OUTCOME 
Survival rate for young men was 84% compared to 75% in older 
men after 7 years of myocardial infarction, whereas it was 90% for young 
women and 77% older women. 
Recurrent infarctions and mortality risks were documented in 
patients less than 45 years of ages who were followed up after acute 
myocardial infarction for 6 to 9 years period, and the event rate was 
found to be around 50 % which include coronary revascularisation, acute 
myocardial infarction and death. 
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Secondary preventive measures like intensive efforts to reduce risk factor 
should be appropriately initiated which includes cessation of smoking, 
physical exercise program, management of obesity and depression, 
diabetes and hypertension. 
CORONARY CARE UNITS 
Till 1961subjects who presented with AMI were admitted in the 
hospital in a separate room remote from the nursing station to assure 
adequate rest to the patients. But a lot of the times patient were found 
dead in their beds. Almost 30 % of  patients who got admitted with AMI 
were found dead due to possible arrhythmia108.This led the physicians to 
establish CCU for all time monitoring of patients through ECG,along 
with defibrillators and other resuscitation measures. This resulted in 50 % 
reduction in CVD mortality in hospital admitted patients with MI. 
INVASIVE CARDIOLOGY 
William Harvey in the year 1628 was the first to describe cardiac 
function and coronary circulation109. This gave the physiologist from 
France C.Bernard the idea to catheterize animals. He measured aortic 
pressure and pressure in the heart chambers110. W.Forrsmanin the year 
1929 tried catheterising himself and this was the first experimental 
catheterisation done in humans. This was followed by study on 
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hemodynamic of the heart by the two physicians AF Cournand and WW 
Richards111. C.Bernard, Werner Frosman Cournand and WW Richards all 
were given Nobel Prize in the year 1956 for their contribution in the field 
of medicine112. In 1958 this along with ventriculography became a 
valuable tool to assess the coronary artery anatomy and ventricular 
function 113.This was followed by exploration of heart through surgical 
techniques for revascularisation114.Though A Gruntzig was called as the 
father of PCI, the contribution done by Dotter and Judkins in the field of 
invasive cardiology was remarkable. In the current set up DES (drug 
eluting stents) are more commonly used rather than routine BMS (bare 
metal stents) to prevent restenosis115.  
NEWER MODALITIES OF TREATMENT 
In the year 1970 the mortality of patients admitted in the hospital 
for MI the one year after discharge was studied and it was found to be 
around 15 percent. Among them 10 percent deaths were due to heart 
failure secondary to large size of the infarct. In a study done on animals it 
was found that the size of the infarct can be decreased altering myocardial 
oxygen demand and oxygen supply116. Fibrinolytics came in to existence 
in the year1976and were found to lyse the clot in acute MI patients they 
were given as an infusion in to the heart117. In the GISSI study which 
included about ten thousand subjects the efficacy of streptokinase 
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infusion intravenously in reducing CVD mortality in AMI was 
confirmed118. This study was followed by ISIS-2 study in which 
antiplatelets like aspirin along with the fibrinolytic agent were found to 
decrease death in CVD patients further119. The mortality rate was found 
to be very low with newer modalities of treatment like angioplasty with 
stents especially drug eluting stents, newer anti-platelets and was found to 
be as low as 7 percent120. All these modalities of treatment have added 
advantage only when patient present early to the hospital after initiation 
of symptoms121.   
 SAVE, a randomised control trial suggested long duration of 
treatment with ACEI in patient with MI with LVD (left ventricular 
dysfunction) as it was proven to decrease the mortality in these 
patients122.  
 Usage of β-blockers, aldosterone antagonist was found to have 
remodelling effect on infarcted myocardium and has reduced the 
mortality in MI patients further. But even then the possibility of 
developing severe LVD when patient develops large infarction secondary 
to excessive scarring of the ventricle exixts. The mortality in these 
patients can be reduced by ID123 (implantable defibrillator), CRT (cardiac 
resynchronization therapy), pacemaker124 and through assistive devices 
for ventricles125.Heart failure patients have defect in calcium pump 
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SERCA 2a. In a pilot study it was found that through gene therapy using 
adenovirus, gene for SERCA 2a can be delivered as infusion into the 
coronaries to improve the function of cardiacmyocytes 126and was found 
to have proven benefit.  
NSTEMI / UNSTABLE ANGINA 
Ischemic heart disease patients can be broadly divided in to two 
categories i.e. those who have coronary artery disease for long time and 
those who presents acutely. Those patients who present acutely may have 
STEMI or unstable angina/NSTEMI. STEMI/NSTEMI though appears 
different represents necrosis of the myocardial tissue (AMI). ST elevation 
in ECG with elevated cardiac biomarkers and presence of typical anginal 
symptoms is called as STEMI, whereas ST segment depression and T 
wave inversion along with raised cariac biomarkers and presence of 
typical anginal symptoms is called as NSTEMI. The difference is due to 
the size of the area infracted.They both cause release of cardiac 
biomarkers which helps to differentiate them from unstable angina. 
Hence unstable angina cannot be called as myocardial infarction. 
Recently ESC/ACC proposed a new definition i.e, amount of necrosis 
produced by ischemia can be STEMI/NSTEMI. NSTEMI and unstable 
angina patient needs treatment with dual anti-platelets therapy plus 
anticoagulant (LMWH), statins, adequate bed rest and needs continuous 
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monitoring as they are more prone for arrhythmias. And it was found that 
level of cardiac biomarker is directly proportional to the mortality and 
there is a definite indication to continue lipid lowering drugs127 and 
anticoagulant usage in such patients128. 
SIGNIFICANCE OF MOLECULAR STUDY IN CORONARY 
ARTERY DISEASE 
The familial risk factors of the CAD and atherosclerosis were 
extensively studied by genomic study144, 145. From these studies it was 
found that various chromosomes with different genes synthesising 
different proteins causing lipid level alterations. It was also found that the 
inflammatory process involved in the development of CAD secondary to 
atherosclerosis was due to the link between SNP’s with chemokines. 
Hence the knowledge on molecular targeting became essential145. 
For drug dosage and selection the pharmaco-genomics which gives 
us the information about genetic difference in the response to drugs in 
different patients is essential. Fourty percent of the patient receiving same 
warfarin dose in a study, showed variation in two genes which codes for 
the liver metabolism of warfarin. Similarly clopidogrel showed less 
efficacy due to variation in cytochrome genes, increasing the mortality in 
these patients and there is also a increased risk of developing CAD146.  
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Numerous clinical trials using progenitor cells to repair the 
myocardial insult are on and results are awaited 147-149. It was also found 
that tendency of the stem cells to migrate inside the body in response to 
various paracrine signals has received much attention because this can be 
used to rejuvenate injured cardiac tissue150.  
BURDEN OF NON-COMMUNICABLE DISEASE  
The global incidence of CAD is evolving slowly that it is varying 
widely among different age, gender and social quality of life among 
different societies. This is evident by the increasing occurrences of CAD 
in under developed countries . In a study done by WHO in the year 2002 
it was found that non-communicable disease accounted for 32 million 
deaths worldwide, which was nearly three fourth of the global death rate. 
For instance, south East Asia in 2002 had nearly 7,413,100 deaths due to 
non-communicable disease. 
 It thus the major mortality factor worldwide except in Africa. So 
overall IHD was found to be the leading cause of mortality in subjects 
aged greater than or equal to 60 and it stands second only to HIV in the 
younger group aged below 60 years151, 152. The increased expectancy of 
life among Indians has made prevalence of CVD to rise, as the disease 
process starts producing manifestation more commonly at the later ages 
of life. 
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CARDIOVASCULAR DISEASE IN INDIA 
In the past few decades the risk of developing CVD in India seems 
increasing compared to foreign nations153. Various studies conducted on 
Indians residing in different nations showed Indians have more than 3 
times higher risk of developing atherosclerotic cardiovascular disease 
than compared people living in America, 6 times when compared to 
China and 20 times when compared to people in Japan154-15. 
As there was no proper maintenance of death register in India it 
became difficult to assess actual burden of the disease that time158.  
Different other studies done independently in north India showed 
increasing trend in the distribution of CAD among rural and urban 
population159, 160. It was found from one study that the disease burden 
rised in urban Indian population from 1% to 10% and there was two fold 
increase in the mortality due to CAD in rural India compared to previous 
years(with south Indian rural population having highest prevalence of 
7%)169.  Also the disease burden was higher in south India than compared 
to north and it was 14%161,162,163.  
In rural India, a twofold increase has been reported in the northern 
states164-168.The incidence keeps rising in the younger in younger 
individuals especially in the working age group i.e. 35-64 years which 
comes around 12 to 16 percent of the population170, 171. In India 50% of 
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the death due to cardiovascular disease is under the age of 50 years and 
25 percent of the cases with AMI are under the age group of 40 172 ,which 
was similar that of the INTERHEART study173. In  Asia, Indians have the 
highest chance of developing CAD. The percentage of patients below 40 
years who experience first attack was found to be 4.4 and 9.7% among 
Asian men and women respectively, this is twice as high as European and 
the third highest in the world173.This study concluded that Indians have 
higher chance of developing MI even before the age of 40. 
CREATE REGISTRY STUDY  
In this study 20,937 patients were registered from 88 centres from 
various regions and cities in India17.. Of this 60.6% patients had STEMI 
.These STEMI patients were found to have an average age of 56 years, 
whereas in NSTEMI it was 59.3 years. They were from middle and poor 
socioeconomic class (52.3 and 19.6%).The average time taken to the 
hospitilisation from the onset of symptoms was 360mins and for the 
initiation of thrombolysis was 50 mins on average. Of the total patients in 
this registry, it was found that diabetics were 6226, hypertensives 7220 
and smokers 8242. 
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TABLE 4: PREFERRED TREATMENT OPTIONS PRACTISED IN 
STEMI/NSTEMI 
TREATMENT STEMI (in %) NSTEMI (in %) 
Anti platelets 98.2 97.4 
ACEI/ARB 60.5 51.2 
Statins 50.8 53.9 
Beta blocker 57.5 61.9 
CABG174 1.9 4.4 
PCI 8 6.7 
 
Most of the STEMI were treated with anti- platelets, ACE inhibitors/ARB 
and PCI, whereas NSTEMI patients received more of Beta blockers, anti- 
lipidemics and CABG. The outcome was measured in terms of stroke, 
chances of reinfarction and death. 
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TABLE 5: OUTCOME IN PATIENTS WITH STEMI/NSTEMI 
PARAMETERS STEMI ( in %) NSTEMI (in %) 
STROKE 0.7 0.3 
REINFARCTION 2.3 1.2 
DEATH 8.6 3.7 
 
From this it is evident that NSTEMI had better prognosis than STEMI. 
The outcome was also determined by the social class of the patient, where 
60.9% of the rich received thrombolytic but only 49.6% of the poor. Of 
rich 61.2% received anti-lipidemics compared to 36% of the poor. ACEI 
/ARB, PCI/CABG were more commonly used in the rich. 
RISK FACTORS AMONG INDIANS 
The main disadvantage of the previous studies on the causative 
factors of premature CAD was that it was mostly done with migrant 
population of India. As a result, the outcome of these studies cannot be 
generalised because a large proportion of the study sample were from 
same community and certain communities were either small in proportion 
or neglected in the study. 
Indians have had cardiac illness 5 to 10 yrs earlier than the rest of 
the world179, 180. 
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From the INTERHEART STUDY22, it was found that the South 
Asians have 53 years as the average age of onset of the acute Myocardial 
Infarction when compared to the western countries the mean age was 
only 63 years, with more incidence among men. From this study it was 
evident that the onset of initial symptom of MI among Asian women was 
58 years whereas it was 54 years among the Asian men. Even though 
Asian women have delayed age of onset of the disease, they have poor 
prognosis than Asian men181-185. The reason for this increased mortality 
due to MI among young Asian women is not clear.      
The INTERHEART study173 which involved 52 countries 
established a significant co-relation between various modifiable causative 
factors among different regions, sex and ages. The Apo protein B / Apo 
protein A1 and smoking had an odd ratio of 3.81 and 2.43 were found to 
be the major causative factors among South Asians. Worldwide the 
psychological factors had an odds ratio of 2.67 whereas in South Asia it 
was only 2.15, but the HTN, truncal obesity and DM had greater odds 
ratio of 2.89, 2.43, and 2.48 respectively among young Asians. It was also 
found from the INTERHEART STUDY173, young women with DM and 
increased blood pressure had higher risk of developing CAD than young 
men in India. 
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The Jaipur Heart Study-2 showed a significant relation between 
smoking, sedentary lifestyle, deranged lipid profile, increased blood 
pressure and abdominal adiposity and CAD among the young men and 
women of  Jaipur186. There was also considerable increase in the 
existence of abdominal adiposity, DM and deranged lipid profile in the 
same population when compared with the old Jaipur Heart Study 
conducted at 1990. It became evident from various studies that upper 
socioeconomic class population had increased existence of DM and 
increased blood pressure when compared to the lower class population in 
Chennai city187.  
There was wide variation in the lipid range among the CAD 
population in North and South India when compared with the non CAD 
population. The population from Northern part of India had prevalence of 
CAD at lower levels of cholesterol and there was a greater correlation 
between total cholesterol and LDL in CAD prone young population of 
India (less than 40 years of age). Low HDL-C and high triglyceride levels 
were the major causative factors among both young and old population of 
India195, 196. The major attributable risk factor in the Indian population 
was deranged APO B / APO A1 levels in both men and women. Many 
studies showed that young males of India had lower existence of HTN 
and DM than the young women population of India189, 190. 
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Sedentary lifestyle and smoking were more common among urban 
population of 20 to 39 years of age in India 186.  
From the INTERHEART study173, it was also evident that smoking 
was a major causative factor among the younger men in India, thereby 
increasing the risk of coronary artery disease among this population. It 
became evident that there is no safe range for smoking by comparing the 
OR of smokers (>40 cigarettes/day) which was 9.16 to those of non-
smokers it was only 1.38. Many other Indian studies also found that 
greater correlation existed between smoking and CAD among young 
Indian population191, 194. It has been found that there is a higher existence 
of smoking, about 44.6 percent in south Indian men and 45.3 percent 
passive smoking in south Indian women than the northern population of 
India161. On the contrary the rural population of India did not have 
smoking as major causative factor for acute myocardial infarction, but 
they had increased blood sugar levels and their waist: hip ratio was 
normal197.  Positive family history for CAD became a significant 
causative factor for CAD among young Indian population 188-191.   
From INTERHEART study173, positive family history was 
significantly higher among the younger CAD patients with a PAR 
(Population Attributable Risk) of 14.8 % to only 10.45% among older 
population. When compared to other causative factors the contribution 
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attributed by positive family history for development of CAD is only by 
1%. But it should be kept in mind that various other correctable causative 
factors for CAD (like cholesterol levels, obesity etc) were also 
determined genetically to some extent. The genetic study became 
significant as familial CAD occurrence emerged in as the second major 
causative factor for CAD among young population in India 194. 
DIABETES MELLITUS AND CAD 
Diabetes mellitus is characterised by insufficient production of 
insulin or by the failure to respond appropriately to insulin, resulting in 
hyperglycaemia. The diagnostic criteria are summarized in Table 1. 
Importantly, new to the diagnostic criteria in glycosylated haemoglobin 
(A1C) level > 6.5% has been added. Type  2 diabetes , characterised by 
relative insulin deficiency with the backdrop of insulin resistance and 
representing  >90% of all diabetes cases. Type 1 diabetes is characterised 
by absolute insulin deficiency. 
 Diabetes is among the most common chronic diseases in the 
world, affecting an estimated 180 million people in 2008199. Confounding 
this high global burden is the increasing incidence and prevalence of type 
2 diabetes, driven by increasing population age, obesity and physical 
activity as well as by the increasing longevity of patients with diabetes. 
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Estimates project that more than 360 million persons will be affected by 
diabetes by 2030. 
Table 6: American diabetes association criteria for diagnosis 
 of DM198 
      Fasting blood sugar >126 mg/dl 
      Or 
      2 hour post prandial blood sugar >220mg/dl with 75-g oral glucose tolerance   
      test 
      Or 
      Symptoms of  hyperglycemia  plus nonfasting  plasma glucose  >11.1   
     mmol/liter( >200mg/dl) 
      Or 
      HbA1c >6.5% 
Previously much attention was given to prevent micro vascular 
complications this led to the shift in trend towards development of macro 
vessel complications related to coronary vessel, peripheral vessel and 
cerebral vessels. This emphasis on to look for cardiovascular disease risk 
especially in people with DM as it can cause major public health 
problem. 
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Comparing with non diabetic individuals, patients with diabetes have a 2-
4 times increased risk for development and dying of CHD200. Previous 
studies showed that there were no significant difference in the risk of 
development of cardiovascular disease in relation to whether patient was 
a diabetic or non diabetic (pertaining to MI), that is, a “coronary disease 
equivalent”, more recent observations from clinical trials suggests a 
substantially lower CHD risk, most likely reflecting the effectiveness of 
contemporary therapeutic interventions201-203. Diabetes is associated with 
an increasing risk for MI. Across the spectrum of ACS events, in which 
diabetes , may affect more than one third of patients,204 patients with 
diabetes have worse CVD outcomes.205  Despite overall improvements in 
outcomes during the past several decades for ACS, the gradient of risk 
associated with diabetes persists.205Furthermore, the increased risk 
observed with the diabetes in the setting of ACS events extends to 
glucose values in the range well below the diabetes threshold, whether it 
is analysed by glucose values at the times of presentation or those 
observed  throughout hospitalisation.206  
 Diabetic individuals are more prone for developing complications 
secondary to atherosclerosis which has its impact on outcome 
independent of primary and secondary prevention strategy. 
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PREDIABETES AND CAD 
Most of the American citizens around 36 million were found to 
have intolerance to glucose, this when combined with obesity will result 
in development of overt diabetes, resistance to insulin and cardiovascular 
disease over a period of time207.CVD risk started to rise even before the 
development of overt diabetes, this was proved in a study called the 
Nurse health study which showed that the late onset diabetics were shown 
to have 3 fold risk of developing MI even before establishing diagnosis of 
overt diabetes which is equivalent to those who already have diabetes for 
long time i.e. in overt diabetes at the entry of the study208. 
Although hyperglycemia associates with vascular complications, 
resistance to insulin alone can increase development of atherosclerosis 
before the patient develop overt diabetes and the available data also 
proves this. All this made health professionals to search for MS 
components in individuals at high risk of developing CVD. 
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TABLE.7:  MECHANISM IMPLICATED IN DIABETIC VASCULAR 
DISEASE 
 
 
 
 
Endothelium 
↑ NF-kβ activation 
↓Nitric oxide production 
↓ Prostacyclin bioavailability 
↑ Endothelin 1 activity 
↑Angiotensin II activity 
↑cyclooxygenase 2 activity 
↑ Thromboxane A2 activity 
↑Reactive oxygen species 
↑ Lipid peroxidation products 
↓ Endothelium-dependent 
relaxation 
↑ RAGE expression 
 
Vascular smooth muscle cells and 
vascular matrix 
↑Proliferation and migration into 
intima 
↑Increased matrix degradation 
Altered matrix components 
Inflammation ↑ IL-1β,IL-6,CD36,MCP-1 
↑ICAMs, VCAMs, and  selectins 
↑Activity of protein kinase C 
↑ AGEs and AGE/RAGE 
 
AGEs- advanced glycation end products; ICAMs-intracellular 
adhesion molecules; IL-interleukin ; MCP- monocyte chemo attractant 
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protein; NF-nuclear factor; RAGE- receptor for advance glycation end 
products; VCAMs-vascular cell adhesion molecules. 
Elevated glucose level has its role in development of atheroma 
directly by increasing the following parameters in the blood 
1. FFA (Free Fatty Acids) 
2. Advanced end products of glycation 
3. Inflammation of vascular system 
4. Endothelial dysfunction 
All these speed up the process of developing atheromatous plaque and its 
rupture. 
In addition, the pernicious effect of hypoglycaemia complicating 
diabetes therapy, the sympathovagal imbalance due to diabetic autonomic 
neuropathy, and vascular effects of exposure to excess insulin may 
contribute to atherosclerotic risk. 
Endothelial dysfunction, a hallmark of diabetic vascular disease, is 
associated with increased hypertension and adverse CVD outcomes. The 
myriad mechanism contributing to endothelial dysfunction include 
abnormal nitric oxide biology and angiotensin II, and reduced 
prostacyclin activity, all of which contribute to abnormal control of blood 
flow. In the setting of ACS events, no reflow after percutaneous 
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intervention reflecting acute endothelial dysfunction occurs more 
commonly in the presence of diabetes or hyperglycemia and may 
contribute to increased myocardial jeopardy, resulting in larger infarcts, 
increased arrhythmia, and worse systolic function. 
Diabetic dyslipidemia is characterised by high triglyceride levels, 
low HDL and increased atherogenic small dense LDL particles, each of 
which is likely to contribute to the accelerated development and 
progression of atherosclerosis. Perturbations in the fibrinolytic system 
and platelet biology further compound the direct vascular effect of 
diabetes, yielding a constitutive prothrombotic milieu. These 
abnormalities include increased circulating tissue factor, factor VII, Von 
Willebrand factor, plasminogen activation inhibitor 1, with decreased 
levels of anti-thrombin III and protein C. In addition, disturbances of 
platelet activation, aggregation, morphology and life span further 
contribute to increased thrombotic potential, as well as to the acceleration 
of atherosclerosis. 
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TABLE 8: ABNORMALITIES OF PLATELET FUNCTION ASSOCIATED 
WITH DIABETES 
Reduced membrane fluidity 
Altered ca2+   and Mg2+  homeostasis 
Increases  
1. Arachidonic acid metabolism 
2. Thromboxane A2 synthesis 
3. Oxidation of free radicals 
4. Adhesion molecule expression on cell surface of endothelium like 
glycoprotein IIb/IIIa which help in adhesion of platelets. 
Decreases 
1. Nitric oxide synthesis 
2. Synthesis of prostacyclins 
Increased platelet micro particle formation 
Increased platelet turnover 
 
Increased systemic inflammation secondary to poor glycemic 
control increases the possibility of developing overt diabetes and diabetic 
atherosclerotic disease, this together with oxidative stress and deposition 
of end products of glycation aggravates the progression of the whole 
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disease process , yielding plaques with characteristics of higher risk in 
both coronary and carotid arteries. 
PREDIABETES AND CAD –EVIDENCE 
A meta-analysis209 with regards to relative risk,the development of 
CVD in patients with impaired glucose tolerance ranges up to 1.30 and 
with impaired fasting glucose it is 1.37. This risk increases 
proportionately with increase in fasting blood glucose from 100 to 110 
mg/dl. This differs between men and women. 
However there is no significant data available on patients with 
impaired glucose tolerance or impaired fasting glucose levels in the 
recent past. This is attributed to the fact that previous studies used WHO 
criteria that says fasting blood sugar greater than 140 and two hour post 
prandial blood sugar between 140 to 200 was considered significant. 
However they found that 2 – fold increase in the CVD risk in the patients 
studied.  
A study was carried out in the year 2001,called the DECODE study 
which says that there were no significant difference between male and 
female with respect to relative risk of developing CVD in IGT patients210. 
The possibility of developing CVD in patients with pre-diabetes if 
they did not progress to overt diabetes in not clearly known or studied211. 
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It is also difficult to screen individuals with regards to prediabetes. Some 
studies support screening patients with prediabetes and others do not. 
American diabetic association says it is important to screen prediabetic 
patients who are at risk of developing CVD or overt diabetes based on the 
knowledge of WC/BMI/age etc 
In summary the burden of the CVD risk in prediabetic remains 
unclear. People like Americans, Indians are at increased risk of 
developing diabetes and they recommend regular screening for 
development of CVD and diabetes  in these individuals.. 
PRE-DIABETES IN INDIA 
In Asians especially south Asians MS is more prevalent, this is due 
to the fact that south Asians have increased body fat with metabolic 
abnormalities at low WC or BMI. Criteria that we routinely use when 
applied on these patient may result in spuriously lower prevalence or 
distribution of MS. To overcome this SAM-NCEP developed a criteria 
which has suggested to keep abdominal adiposity component as an 
optional one. But IDA (International Diabetic Federation) has suggested 
ethnic and race specific cut-off to avoid under estimation of actual 
distribution of MS in the community. 
The risk for developing CVD in Asian Indians is 2-fold higher 
when compared to other foreign nations. This is attributed to high 
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prevalence of hypertriglyceridemia and low HDL cholesterol levels in 
blood. Hence Asians especially south Asians have high chance of 
developing CVD which needs active intervention by life style and 
behavioural modification starting early in life. 
PHENOTYPIC VARIATION IN ASIANS 
Asians, especially Asian Indians though phenotypically donot look obese, 
their metabolic parameters appears deranged most of the times212. Hence 
they cannot be considered normal even when their BMI falls less than 25.  
Compared to India western countries have only 6% of population 
comprising the above mentioned phenotype213. This is attributed to 
certain features which are unique to Indian population. These includes  
1. High degree of lipid derangement 
2. Decreased adiponectin levels 
3. Hips are thinner but have increased waist circumference 
4. Legs are short 
5. Increased fat deposition in the viscera 
All these factors predisposes to increased risk of developing CVD and 
DM214. 
Increased fat deposition in viscera which is disproportionate to the 
corresponding waist circumference makes them more prone to develop 
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resistance to insulin.This is commonly seen starting from the age as 
earlier as eight years215. 
Children in India have higher insulin levels compared to their 
counter parts in other nations with relation to waist circumference. All the 
above mentioned factors together with higher concentration of PAI-1 
levels and fibrinogen levels in South Asian population makes them more 
prone to develop CVD and DM216. 
DIFFERING CRITERIAS IN ASIANS 
Because of the above mentioned observations, the following difference 
has been made in the criteria’s previously established 
1. In WHO –for Asians they have decreased the BMI cut offs has been   
declared or more 23 in the overweight category and more than 25 for 
obese individuals217. Based on the above change in the criteria, 
UKDAS218 study was carried out. In the study they found that most 
DM patients belong to the category of overweight and obese which is 
around 95% and 80% in South Asia respectively. It was also 
suggested that usage of waist circumference cut-off of 87 cms and 82 
cms for males and females could definitely help in identifying 
correctly the individuals at risk of developing DM and CVD in Asian 
Indians dwelling in urban areas219. 
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2. The IDF proposed the waist circumference cut off  to be 90 and 80  
cms for men and women dwelling in South east Asia220. 
3.  AHA/NHLBI in the year 2005 has reduced the waist circumference 
cut-off for Asians living in America to less than 90cms and 80 cms 
for men and women221. 
4.  The South Asians modified (SAM) NCEP guidelines is almost the 
same as IDF criteria but the exception is abdominal adiposity which 
was not considered as a principal component but was kept optional221-
222
. 
When applied to the study population an increase in the prevalence of 
obesity from 25 percent to 50 percent was found 
Thus MS is more prevalent in south Asians than compared to 
Europeans and other Asians. Implementing primary and secondary 
prevention strategies becomes essential to control the prevalence of DM 
and CVD related morbidity and mortality. Hence weight reduction, 
regular exercises, and low fat/ anti atherogenic diet starting from 
childhood years is vital to stop further progression of this metabolic 
abnormality to become overt diabetes and CVD. 
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Consensus statement for revised cut-off for abdominal obesity in 
Asian Indians: 
Methodologies of WC measurements are as follows: 
With the patient standing, using a flexible tape at a point above 
iliac crest, ideally in the empty stomach, and during expiration waist 
circumference should be measured. 
For measuring abdominal adiposity most study recommend the 
usage of waist circumference as more reliable than  measuring WHR that 
too especially in Asians as ethnic and race specific cut-offs are available.  
Table 9: WAIST CUT-OFFS AND SUGGESTIONS 
            WC  in Asians(in cms)                  Suggestions 
78 for male and 72 for female WC higher than the mentioned 
values are suggested not to gain 
weight. 
Physical exercises are advised. 
90 for men and 80 for women Advised to seek help from medical 
professionals for reducing weight. 
To be investigated and managed for 
other related risks 
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There are inherent difficulties in obtaining hip circumference 
accurately in community settings. Furthermore, changes in WHR may not 
reflect changes in adiposity accurately and the ratio may be normal in 
generalised or gynaecoid obesity. Hence the consensus group opined that 
it may not be used routinely as a measure of abdominal obesity. 
VITAMIN D AND METABOLIC SYNDROME: 
  Metabolic syndrome is characterized by hypertension, 
hyperlipidemia , and insulin resistance , with or without obesity, all of 
which have been linked to vitamin D nutrition (VDN). Vitamin-D 
deficiency is more commonly seen in patients with metabolic syndrome, 
but it is unclear that whether this is a cause or a consequence of the 
associated obesity. Patients with low levels of 1,25-dihydroxy vitaminD3 
were found to have high levels of VLDL and hypertriglyceridemia. This 
may be attributed to the development of resistance to insulin action in 
patients with deficiency of Vitamin D and this finally results in MS223. 
This relationship with vitamin D deficiency was established both in 
experimental animals and in human observational studies224,225 The 
proposed mechanism for developing diabetes- like state in subjects with 
vitamin D deficiency include  
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     1. Altered calcium homeostasis in β-cells of the pancreas 
2. Altered expression of insulin receptors on the cell surface 
3. Development chronic inflammatory state225,226 
     4. Decreased expression of insulin receptor on the cell surface leads to 
insulin resistance thereby developing a pseudo diabetic state. 
     5.  Transport of glucose in to the cells were also disturbed in the back 
ground of vitamin-D deficiency229,230. 
This was evaluated by studies done on animal models which 
showed decreased secretion of  insulin after ingestion of glucose, though 
its basal level of insulin remain unaltered in a vitamin D receptor knocked 
out mouse226-228. 
It was found in many studies that deficiency of vitamin-D was 
more common in subjects with type 2 diabetes mellitus, gestational 
diabetes, and in patients with impaired glucose tolerance.  
In a prospective European Society Study on diabetes prevention 
(EURODIAB231 ) it was found that more than 30 percent decrease in the 
incidence of developing DM in children after supplementation of active 
form of vitamin-D. 
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MICROALBUMINURIA AND VASCULAR ABNORMALITIES 
Microalbuminuria has significant influence on vascular system. 
Several cross sectional studies found that microalbuminuria is associated   
with higher thickness of the intima and media layers of the carotid artery. 
Moreover in a study by Bruneck, a prospective population based survey 
of 683 Caucasians adults, showed albumin creatinine ratio has direct and 
independent relation with severity of atherosclerosis of femoral and 
carotid artery. Moreover increased levels of albumin creatinine ratio are 
associated with silent cerebrovascular disease (silent cerebral infarcts and 
brain micro bleeds). Microalbuminuria also predicts the development and 
progression of carotid atherosclerosis. Hypertensive patients with 
microalbuminuria were more prone to retinal vascular changes. 
Individuals with urine albumin excretion ≥20µg/min had a prevalence of 
hypertensive retinopathy of 69%, significantly higher than that observed 
in subjects with urine albumin excretion ≤11 µg/min. 
In the large Netherland cohort study in the name of PREVEND 
found that there is a significant relationship exist between albuminuria 
and CVD i.e. increased excretion of albumin in the urine will result in 28 
percent raise in the mortality secondary to cardiovascular disease 
cardiovascular diseases and there was a continued association between 
cardiovascular disease and albminuria. Data from NHANES –III study, 
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spanning a thirteen years follow-up of 14586 adults revealed a two fold 
increase in albumin levels in the urine resulted in 6.3 percent raise in 
death related to CVD and the same 6.3 percent raise in death rate 
pertaining to all other cause, adjusting other predictable risk factors. It 
was also found that there were no significant differences in the death rate 
pertaining to albuminuria in diabetic and non diabetic population 
involved in the study.   
MICROALBUMINURIA AS PREDICTOR OF CARDIOVASCULAR 
MORTALITY AND MORBIDITY 
A meta analysis evaluating a relation between microalbuminuria 
and mortality in Type 2 diabetes found that microalbuminuria doubled 
cardiovascular morbidity and more than doubled the all-cause mortality 
rate. Recently, these results were confirmed in HOPE study which 
revealed albumin in urine has direct relation to CVD progression. It 
provides the information that the disease process will start to progress 
even at the albumin level of 4.4mg/gm in the urine. Similar analogous 
results relating urine albumin excretion to cardiovascular risk has been 
shown in Copenhagen Heart Study and LIFE trials. 
Studies like PREVEND, HOORN study, DANISH-MONICA, the 
study Earle et al, showed the strong association of urine albumin 
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excretion with ischemic heart diseases, silent myocardial MI, and resting 
ECG abnormalities. 
Studies like EPIC- Norfolk, Shibata study, Portland study, associated 
strongly, urine albumin excretion to strokes and recurrent strokes. Finally 
cross sectional studies like Zerden et al showed urine albumin excretion’s 
close association with peripheral arterial disease. 
TREATMENT OF MICROALBUMINURIA 
Clinical trials showed proven benefit of using angiotensin 
converting enzyme inhibitors in controlling excretion of albumin in urine 
that too especially in diabetics. 
ARB’s were also found to have similar role like that of ACEI in 
controlling protein excretion in urine. 
GAG and Diuretics like thiazides was also found to be beneficial in 
this aspect. 
Reduced salt intake, adequate blood sugar control helps preventing 
microalbuminuria thereby preventing overt protein excretion and diabetic 
nephropathy. 
Adequate control of CVD, metabolic disease control can be 
established by identification of development of microalbuminuria in 
69

patients by implementing life style management and control of other 
causative factors232-234 
METABOLIC SYNDROME AND LV DYSFUNCTION 
Numerous studies conducted on patients with MS revealed the 
presence of diastolic dysfunction more common than systolic 
dysfunction. Patient with MS were found to have decreased E/A ratio and 
the number of criteria has a direct relationship  i.e the more number of 
MS features present in a subject the more likely is the chance of 
developing worsening diastolic function. 
Many were found to have normal ejection fraction with poor 
diastolic function called by HFNEF (Heart Failure with Normal Ejection 
Fraction). All the above findings were confirmed individually through 
following studies Lisa235 et al, H Masugata236 et al, and Azevedo237 A, et 
al. 
MS-PAST/PRESENT/ FUTURE 
Primitive man developed a the features that go to make the 
metabolic syndrome (MS) in the body to withstand periods of starvation 
and drought. Those who inherited the genes for MS survived by storing 
energy in the form of fat so that during periods of famine sufficient 
energy to survive was available. Fifty percent of the MS is due to genetics 
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and /or the uterine environment. During critical periods of intrauterine 
development, in the process of survival and to conserve energy to the 
growing foetus, the foetus becomes resistant to the action of insulin. 
Although later in life this in-utero acquired insulin resistance, may help 
protect against starvation, in the modern day environment their is 
excessive availability and utilization of calories, fats and carbohydrates. 
This resistance to the action of insulin becomes pathological. This is 
particularly true if following the birth of a small baby ‘catch up’ growth 
occurs. The finding that the intrauterine environment , through genetic 
imprinting is more important than the true genetics of the foetus, comes 
from the recent observation of the children born to the mothers who have 
previously lost weight through bariatric surgery are less resistance to the 
action of insulin than are those born at the time of the previous greater 
maternal obesity. Birth weight is one of the important deciding factors 
that determine the chance getting MS in the future. 
Initially MS was found to be associated with diabetes mellitus, and 
later with cardiovascular disease. But now it acts as an independent factor 
which even in the absence of DM,which forms a predilection to develop 
cardiovascular disease, stroke, and all cause mortality. In recent times we 
find there is no shortage of calories but shortage of burning of the same – 
physical activity. The plentiful supply of inexpensive yet luxuriously 
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caloric food with high saturated fat content, soft drinks and syrup 
containing fructose are probably the forerunners of obesity predominantly 
abdominal. Increased life expectancy, (ageing population) is also 
responsible for the exacerbation of metabolic syndrome and hence 
prevalence of T2DM and CVD. Thus MS which provided a survival 
advantage in our ancestors, has now become a health hazard in current 
day life scenario full of stress, high caloric diet and sedentary living. 
The future of MS, DM and CVD may in all probability merge into 
each other and modify our basic understanding of these disorders that are 
probably based on a‘common soil’. Despite all odds, from a clinical point 
of view, the cluster concept becomes very useful and advantageous in 
diagnosing and treating the various manifestations and complications. IR 
with endogenous hyperinsulinemia, large vessel atherosclerosis, pre 
diabetes and T2DM – all may be considered as evolving from one 
another, sometimes preceding and sometimes following each other. The 
main measureable components of MS are central obesity, dysglycemia, 
hypertension and dyslipidemia. These components may need refining and 
redefining in the near future and the years to come. For instance, the 
Insulin clamp study gives us data of fasting triglyceride to HDL ratio to 
correlate well with the criteria of diagnosing MS. Ratio exceeding 3.5 is 
more likely to be MS. Through genetic and environmental factors, excess 
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peritoneal fat infiltrated with macrophages produces excessive FFAs and 
harmful adipocytokines and decreased production of proactive 
adipocytokines – adiponectin. The net effect of this imbalance of 
adipocytokines is inflammation, oxidative stress, endothelial dysfunction, 
insulin sensitivity, excess coagulation, atherosclerosis, T2DM and 
adverse cardiovascular events. 
To the emerging question if there are factors that help to improve 
the manifestations of MS, the response is predictable. Regular exercise 
and dietary strategies to reduce the post prandial spikes in glucose and 
TGs, to reduce the inflammation, oxidative stress and chronic 
degenerative diseases. Dietary advice should emphasise on low glycemic 
index foods which mimic the Mediterranean diet. Low fat dairy products, 
tea, coffee, olive oil, cinnamon and moderate alcohol particularly red 
wine intake – may improve the MS and prevent progression to T2DM. 
There are few drugs which may improve the various components of 
metabolic syndrome. However most physicians lay emphasis on dietary 
and exercise measures to prevent or reverse obesity and IR. 
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METHODOLOGY 
This is a cross-sectional study on young patients admitted to PSG 
hospital with myocardial infarction  
Patients age of 45 years or less were studied as most of the studies 
used age group between 40 and 45 years to describe premature CAD in 
the young70,238-242. The study was conducted over a period of six months 
from March 2014-August 2014. All patients admitted with Acute 
Coronary Syndrome (ACS), both STEMI/NSTEMI and Unstable Angina 
as per standard definition during this period were included in the study 
after consent. The study was conducted in the PSG hospital, the teaching 
affiliate of PSG institute of Medical Sciences and Research (PSG IMS & 
R) which is a teaching and tertiary care referral hospital located in the 
city of Coimbatore, Tamil Nadu. 
The patient who did not get the complete evaluation including 
coronary angiogram for various reasons were excluded from the study. 
The purpose of this study was explained to patients and relatives 
and consent was obtained. The study was approved by Human Ethics 
Committee of the institution before commencement. 
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INCLUSION CRITERIA 
1. Patient with evidence of coronary artery disease proven by 
coronary angiogram 
2. Age 45 years or less 
3. Both sexes were included 
EXCLUSION CRITERIA 
1. The patient who did not undergo coronary angiogram for various 
reasons. 
2. Age more than 45 years 
All patients with coronary artery disease including 
STEMI/NSTEMI/Unstable angina were included in the study. 
Patients with signs and symptoms suggestive of MI (as described by 
European Society of Cardiology-Joint Committee) were subjected to 
coronary angiogram.  
CRITERIA FOR DIAGNOSIS OF MS 
The IDF criteria for diagnosis of metabolic syndrome (MS) were 
used. This definition identifies metabolic syndrome with abdominal 
obesity as principle component with any two or more of the incoming 
variables 
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1. Fasting hypertriglyceridemia (mg/dl) >150 or any medications for 
the same. 
2. Decreased high density lipoprotein cholesterol value (in mg/dl) 
<40 in men and <50 in women or any medications for same. 
3.  Elevated Blood pressure >130/85mmHg or any medications for 
SHT. 
4. Increased fasting plasma glucose (in mg/dl) ≥100 mg/dl or 
previously known to have medications for diabetes mellitus 
Detailed history was taken including presenting symptoms, past 
history of diabetes/systemic hypertension /any significant history CAD in 
the family/ whether habituated to alcohol or smoking. 
A careful physical examination was done with reference to WC (Waist 
Circumference) and blood pressure before discharge. About ≥3 
measurements of BP at the time of entry with values greater than 
130/85mmHg on an average or any medications for SHT –was considered 
significant. 
WC was recorded according to the national health and nutritional 
survey243. With patient in the fasting state and standing,  the upper border 
of the iliac crest was palpated and using a flexible tape during expiration 
waist circumference was measured. 
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INVESTIGATIONS 
Following investigations were done for all patients.  
ECG,ECHO 
CARDIAC ENZYMES  
FBS/FLP 
CORONARY ANGIOGRAM (CAG)  
The blood sample were drawn at the time of admission and the 
following morning (lipid profile) and at day 5 for fasting plasma 
glucose.244 
Patients underwent treatment modalities like thrombolysis, Primary 
Percutaneous Coronary Intervention (PCI) or conservative management 
as feasible and required, depending on the clinical circumstances and 
consent from the patient. All the subjects were treated with dual anti-
platelets, statins, low molecular weight heparin and other drugs as per 
standard protocols. 
Coronary angiogram was done in all the subjects either at 
admission for primary PCI or electively after initial medical stabilisation 
with thrombolysis or conservative treatment. 
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STATISTICAL ANALYSIS 
Data collected from the patients were initially entered in to the 
Microsoft excel-sheet and data analysed using SPSS (19). Pearson’s chi-
square was used to compare the proportions and using independent 
sample t test, the means were compared. A Predictive value of less than 
0.05 was taken as statistically significant      
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RESULTS /ANALYSIS 
BASED ON THE ENTRY CRITERION 90 PATIENTS WERE 
STUDIED 
TABLE 10: DISTRIBUTION OF MS 
Number of  CAD patients studied 90 
Number of CAD patients with MS 67 (74.44%) 
 
A total of 90 cases of ACS were admitted during the 6 months of 
study period, out of which 67 cases had MS with over all prevalence of 
74.44% in the present study. 
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TABLE 11: BASELINE AND CLINICAL CHARACTERISTICS OF 
PATIENTS WITH AND WITH OUT METABOLIC SYNDROME 
Variable                                                                  MS                         p value 
YES (n=67)       NO (n=23) 
1.Blood pressure >130/85mmHg            44(65.67%)     6(26.08)                <0.01 
2.Fasting blood glucose>100mg/dl        43(64.17%)     9(39.13%)              <0.05 
3.Triglycerides (mg/dl)                          179.14          115.86                 <0.01 
4. HDL-C (mg/dl)                                       32.36             36.78                   <0.05 
5. WC (in cms)                                           95.64              87.23                 <0.001 
6.Age                                                          40.49            37.39                 <0.01 
7.Diabetes Mellitus                           37(55.22%)          5(21.73%             <0.01 
8.pre existing hypertension               31(46.26%)        3(13.04%)               <0.01 
9.Family history of premature          10(14.92%)        2 (8.69%)              p=0.448 
Coronary artery disease 
10.Smoking                                    42(62.68%)          15(65.21%)           p=0.825 
11.Alcohol consumption               32(47.76%)           13(56.52%)           p=0.468 
12.ST elevation                              36(53.7%)            18(78.26%                 <0.05 
13. LVD                                         23(34.32%)          11(47.82%             p=0.24 
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FIGURE 3: PREVALENCE OF EACH COMPONENT IN THE IN PATIENT 
WITH AND WITH OUT MS 
 
90 patients formed the study group. Of these 90 patients 67 had MS 
(74.44%) and 23 (25.55%) did not. 
Of these 67patients with MS, 29 (43.28%) met 3 out of 5 criteria 
for MS, 24 (35.82%) met 4 of these 5 criteria and 14 (20.89%) met all the 
5 criteria for MS. 
The distribution of IDF criteria in those 67 patients diagnosed to 
have MS are given below   
HDL-CHOLESTEROL 
Patients with metabolic syndrome had an average HDL-cholesterol 
level of about 32.36, whereas in non-MS group the average value was 
36.78 which is statistically significant. 
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TRIGLYCERIDES 
The average triglyceride value in MS group was 179.14,whereas in 
non-MS group it was 115.86 which is statistically significant. 
FIGURE 4: COMPARISON OF TRIGLYCERIDES AND HDL LEVELS IN MS 
AND NON MS PATIENTS 
 
FASTING BLOOD GLUCOSE 
Fasting blood glucose was high in 43 patients (64.17%) in MS 
group, whereas it was high only in 9 patients (39.13%) of the non-MS 
group with the p-value of <0.05 which is statistically significant.  
BLOOD PRESSURE 
44 patients (65.67%) of the MS-group and only 6 patients 
(26.08%) of the non-MS group had elevated blood pressure of more than 
130/85mmHg, with the p-value of <0.01 which is statistically significant. 
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WAIST CIRCUMFERENCE 
Average WC of patients in MS group and non-MS group were 95.64 and 
87.23respectively. The p-value came as <0.001 which is statistically very 
significant. 
FIGURE 5: AVEARAGE WAIST CIRCUMFERENCE IN MS AND NON MS 
 
DIABETES MELLITUS 
37 patients (55.22%) in MS-group and 5 patients (21.73%) in non-
MS group already had diabetes and were on treatment. The p-value was 
<0.01 which is statistically significant. 
In 67 patients with MS 14 met all the five criteria, among which 13 
were diabetics. Of the 24 who met 4 criteria for MS 12 were diabetic and 
12 were non-diabetic. Of the remaining 29 who met 3 out of 5 criteria for 
MS 12 were diabetic and 17 were non-diabetic.  
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FIGURE 6: DIABETES AND MS 
 
SYSTEMIC HYPERTENSION  
31 patients (46.26%) with MS were found to have pre-existing  
hypertension compared to 3 (13.04%) in non-MS patients. The p-value 
obtained was <0.01, which is statistically significant. 
FIGURE 7: PREVALENCE OF DM AND HTN IN MS AND NON MS 
 
 



#
"



#
"
&' (' )
*+,'&+,-
&' (' )
*+,'&+,-
&'. (' )
*+,'&+,-

! !



.


#
	/0 1	2

! !
84

AGE 
Average age of the patient presented with AMI in MS and non-MS 
group were 40.49 and 37.39 respectively. The early presentation of CAD 
in non-MS group may probably be due to increased prevalence of 
smoking and alcohol in this group. 
RISK FACTORS 
• FAMILY HISTORY OF CAD 
    10 Patients (14.92%) in the MS group and 2 patients(8.69%) in the 
non-MS group had history suggestive of CAD in the family. 
• SMOKERS 
        42 patients (62.68%) in MS group and 15patients (65.21%) in  
 non-MS group were smokers with p-value of 0.825(not significant) 
• ALCOHOL 
    32 patients (47.76%) in MS group and 13 patients(56.52%) in non 
MS group were alcoholic. p-value obtained was 0.468 which is 
statistically not significant. 
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TABLE 12 : COMPARISON OF RISKFACTORS IN MS  
AND NON MS 
 MS  NON 
MS 
 TOTAL  P-
VALUE 
RISK FACTORS NO % NO % NO %  
DIABETES 37 55.22 5 21.73 42 46.66 <0.01 S  
HYPERTENSION 31 46.26 3 13.04 34 37.77 <0.01 S 
FAMILY 
HISTORY OF 
CAD 
10 14.92 2 8.69 12 13.33 0.448 NS 
SMOKER 42 62.68 15 65.21 57 63.33 0.825 NS 
ALCOHOL 
CONSUMPTION 
32 47.76 13 56.52 45 50 0.468 NS 
 
S-significant,   NS- Non significant 
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FIGURE 8: COMPARISON OF RISKFACTORS IN MS /NON- MS 
 
ST CHANGES IN MS AND NON MS 
36 (53.7%) out of 67 patients in MS group presented with ST 
elevation MI, whereas it is 18(78.26%) out of 23 in NON MS with the p 
value of 0.03 which is statistically significant (this may be attributed to 
occlusion of the vessel by emboli in Non-MS group but whereas in MS 
atherosclerotic occlusion of the vessel is more common than embolic). 
LVD IN MS AND NON MS (EF <50%) 
23(34.32%) out of 67 patients in MS group and 11(47.82%) out of 
23 in NON MS group had LV dysfunction with the p value of 0.24, which 
is statistically not significant. 
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TABLE 13: OTHER RISKFACTORS 
Other factors MS  Non 
MS 
 Total   P value 
 NO % NO  % NO %  
DYSLIPIDEMIA 15 22.3 2 8.69 17 18 0.148 
HYPOTHYROID 2 2.98 0 0 2 2.2 CANNOT BE 
CALCULATED 
ANAEMIA 1 1.49 0 0 1 1.11 CANNOT BE 
CALCULATED 
 
HYPER 
HOMOCYSTEINEMIA 
 
 
0 
 
 
0 
 
 
3 
 
 
13.0 
 
 
3 
 
 
3.3 
 
CANNOT BE 
CALCULATED 
PVOD 1 1.49 0 0 1 1.1 CANNOT BE 
CALCULATED 
 
PVOD = peripheral vessel occlusive disease 
15 patients (22.38%) of MS group and 2 patients (8.69%) in non 
MS group had dyslipidemia and were on treatment ( p value of 0.148-
statistically not significant) 
2 patients (2.98%) in MS group had hypothyroid and 1 patient 
(1.49%) in MS group had anemia (p value cannot be calculated),the 
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significance of which is difficult to assess, given the small number of 
patients studied. 
3 patients (13.04%) in non MS group had hyperhomocysteinemia 
(p value cannot be calculated), the significance of which is difficult to 
assess, given the small number of patients studied 
ANGIOGRAPHY: 
TABLE 14: ANGIOGRPHY RESULTS IN MS/NON MS 
ANGIOGRAM 
RESULT 
MS  NON MS  p VALUE 
 NO % NO %  
SVD 39 58.2 16 69.56 0.335, NS 
DVD 14 20.89 6 26.08 0.605, NS 
TVD 14 20.89 1 4.34 0.066, NS 
SVD = one vessel involved, DVD = two vessels involved 
TVD= three vessels involved, NS = NIL SIGNIFICANT 
39 patients (58.20%) in MS group and 16 patients (69.56%) in non MS 
group had single vessel disease. 
14 patients (20.89%) in MS and 6 patients (26.08%) in non MS group had 
double vessel disease. 
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14 patients (20.89%) in MS and 1 patient(4.34%) in non MS group had 
triple vessel disease. 
p-value obtained were 0.335, 0.605 and 0.066 respectively which were 
statistically not significant. 
FIGURE 9: 
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DISCUSSION 
Syndrome X is a clustering of various factors responsible for 
development of DM and CVD. It comprises of abdominal 
adiposity/SHT/decreased HDL/ hypertriglyceridemia and intolerance to 
glucose. MS presence itself carries double the chance of developing 
atherosclerotic mediated CVD and 6 times the chance of developing DM. 
Younger subjects with premature CAD, most of the time may have 
low cardiovascular disease risk estimates.MS is more commonly seen in 
this group of subjects necessitating multi-factorial risk approach for CAD 
prevention in these candidates with minimal risk for cardiovascular 
disease. 
Its relation with acute coronary syndrome, MS was independent 
from various other confounding factors. Hence identification of subjects 
with MS will definitely be helpful in reducing long term risk, mortality 
and morbidity. 
Several different criteria have been proposed for diagnosis of MS 
by various professional bodies. The most widely used one appears to be 
the one proposed by the IDF (International Diabetic Federation) which 
includes ethnic specific cut-offs for WC. There has been lot of 
controversy regarding whether to accept this concept of MS based on the 
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contention that it does not represent any abnormal patho-physiology and 
the risk attributed by MS is no different to that contributed by each of its 
individual factors. 
However, the concept of MS is very important because it provides 
easy meaningful information which helps the general population and 
professionals, particularly to look for the presence of other causative 
factors in the same subject. 
In the present study which included 90 cases of CAD, MS was 
present in 67 cases (74.44%). 
TABLE 15: COMPARISON OF PREVALENCE OF MS WITH PREVIOUS 
STUDIES 
               Study % of MS in CAD   
Milani R6 et al (2003) 
Niomiya245 et al (2004) 
Levantesi G246 et al (2005)  
Schwartz G247 et al  (2005) 
Zeller M248 et al (2005) 
Present Study  
58 
41.5 
29 
38 
46 
74.44 
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There is increasing evidence regarding development of 
atherosclerotic disease in patient with MS and hence its identification will 
definitely helpful  to prevent further progression to over disease like CVD 
and overt diabetes. Irrespective of FRS estimate its identification in 
patient has related to increased cardio vascular disease risk249.   
In a cross sectional study large number of children and adolescent 
and around 30 percent of the adult population were found to have this 
MS16,22,44. 
Till to date little information is available about the presence and 
distribution of MS in young coronary artery disease patients25,26. Earlier 
studies have inferred that the presence of MS in young CAD patients is 
almost seen in half.  
In studies conducted  by Zarich et al250, reported prevalence of MS 
in two third of the subjects studied regardless of their diabetic status and 
have focussed on the fact that all existing guidelines have not sufficiently 
estimated the risk of coronary artery disease in young population having 
MS. 
Turhan et al26 reported 37% prevalence of MS in Turkish patients 
with premature CAD. In keeping with earlier report MS was present in 
74.4% of patients with premature CAD in our study 251. Framingham risk 
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score was found to be less predictive in diagnosing MS in patients with 
diabetes mellitus252.Diabetes epidemiology.  collaborative analysis of 
diagnostic criteria in Europe have concluded the fact that among their 
study population person with lower CVD risk scoring and co existing MS 
had a significant high risk for fatal CVD than those without the  
syndrome 27. 
In our study we evaluated the prevalence of MS in premature CAD 
patients taking into consideration the fact from previous studies that even 
after adjustment for other risk factors for CAD the presence of MS alone 
had been a major risk factor for CAD with 200% risk especially in a 
population with low Framingham Risk Score 249. Hence we suggest that 
careful clinical assessment of MS to be a important tool in the hands of 
preventive medical care personnel and physicians as its prevalence can 
itself be considered to be a detrimental factor in assessing final end points 
in patients with CAD. In our study prevalence of MS is 74.4% in 
premature CAD while traditional risk factors for CAD like diabetes 
mellitus and systemic hypertension were 55.2% and 46.26% respectively. 
This again supports the inferences from previous studies that MS 
assessment alone can be a significant tool in estimation of risk for CAD 
incidence in young population. 
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The dynamic changing trends of lifestyles in the urban population 
and even the rural population to an extent can be indirectly highlighted 
from the fact that in our study we have 55.2% of population with diabetes 
unlike previous studies where the incidence of diabetes and obesity was 
seen in less than 30% of the study population 253,254. This suggests that 
atherogenic diet intake associated with changing life style, sedentary 
mode of work and increased trends of physical inactivity have increased 
the incidence of MS . Further studies focussed on these lines are 
mandatory to identify the root cause for such drastic elevation in 
incidence of MS and other individual risk factors for CAD in our 
population which can help us in focussing on treatment and prevention of 
these risk factors. However even the well known traditional risk factors 
like (smoking and family history of CAD) for atherosclerosis have to be  
taken into account as many recent studies have shown greater incidence 
of these risk factors in young CAD patients.21,253,254. In our study however  
we had no statistical significance between smoking habit and prevalence 
of MS in patients with young CAD with a p value of  0.825. 
In a study conducted by Uhl et al,159 patients aged less than forty 
years were studied and it was found that SHT and obesity were  
predominant component and  was present in greater than 58% of the 
population studied21. In our study 46.26% of patients in MS group and 
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13.03% in non-MS group had hypertension which is comparatively 
similar to the previous studies mentioned. Another study done by Kelly et 
al on patients with less than 40 years of age who underwent CABG, 
family history of premature CAD and smoking were again the most 
prevalent factor255. In our study traditional risk factors like smoking, 
history of CAD in the family were all found to be insignificant with the p 
value of 0.825 and 0.448 respectively which is statistically insignificant 
The prevalence of DM is 55.22%  and that of systemic 
hypertension was 46.26% in patients with AMI  in MS group in 
comparison with non MS group which showed DM- 21.73% ; SHT – 
13.04%. Elevated fasting blood sugars were seen in 43 patients out of 67 
(64.17%) of MS group while it was 9 patients out of 23 (39.13%) of non 
MS group.  
Among 67 subjects with MS, 29 had only 3 out of 5 criteria for 
MS. Among this 29, 12 were diabetic and 17 were non-diabetic.24 
patients met 4 out of 5 criteria with 12 diabetic and 12 non-diabetic 
patients. 14 out of 67 patients met all the 5 criteria for MS, comprising 13 
diabetic and 1 non-diabetic patients. 
Among MS group of the remaining 30 without diabetes only one 
person had all the MS criteria (whereas among the remaining 13 patients 
who met all the 5 criteria for MS all had overt diabetes), 12 patients met 4 
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out of 5 criteria and 17 patients met only 3 criteria for MS. This emphasis 
the fact that patients with DM are more prone for developing 
cardiovascular disease mortality than those without diabetes. 
High fasting blood glucose or treatment for diabetes is one of the 
diagnostic criteria for MS as per IDF definition. Unlike other studies 
underestimation of  MS on a patient whose is already on treatment for 
diabetes with is not possible in our study.  
Of the 44 patients with high blood pressure, 31 already had 
systemic hypertension and MS was more prevalent in this group with p 
value of less than 0.01 which is statistically significant. The presence of 
diabetes mellitus and systemic hypertension were also associated with 
diastolic and systolic heart dysfunction affecting proper functioning of 
viable myocardium256 explaining the higher incidence of heart failure in 
these patients. In our study, distribution of DM and SHT were high 
compared  to previous other studies mentioned earlier which highlight the 
increased chance of developing complications in these patients in future 
and the need for aggressive control of the disease. 
The average of HDL cholesterol was significantly lower and 
average value of triglycerides were significantly higher in MS group with 
p value of <0.05 and <0.01 respectively. Previously low HDL cholesterol 
was the most observed component26 in both MS and non MS group with 
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mean values lower in the MS group. In our study, high triglycerides were 
the more prevalent component. 
In a study carried out by Misra et al on MS in south Asians they 
found that triglyceride levels were high and the level of HDL was low ,in 
our study Serum triglycerides were very high i.e. 179.14 (97.5%) may be 
related to South Indians  who have high percentage of  body fat and lower 
muscle mass257. Additionally insulin resistance also reduces the 
concentration of lipoprotein lipase in the peripheral tissues258. 
The high triglycerides with low HDL cholesterol in our study may 
be due to triglycerides decreasing the production and increasing the 
clearance of HDL cholesterol from the circulation258,259. 
In our study, possibility of underestimation of lipid levels is unlikely as 
patients with dyslipidemia and lipid lowering drug therapy for the same 
were also included in the diagnostic criteria for MS. 
South Asians when compared to other western nations have BMI 
comparatively low with relatively higher waist circumference. This can 
lead to under estimation of population at risk of developing MS when 
routine conventional criteria designed and framed for people in western 
countries were used. Considering this the IDF criteria were chosen for 
studying the actual prevalence of metabolic syndrome in the young 
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population affected by CAD, as IDF has ethnic and race specific WC cut-
offs which could obviously avoid under estimation of population at risk 
of developing CAD by identifying appropriate distribution of MS in these 
community. The prevalence of MS is recently showing an increasing 
trend due to increased prevalence of traditional risk factors like DM, 
SHT, abdominal adiposity in the community all of which all comes under 
the shades of MS criteria. Hence IDF definition for MS with gender and 
race specific waist circumference cut off was used in this study. Of all the 
5 criteria for MS, waist circumference was the one most prevalent in 
premature CAD patients with metabolic syndrome which is highly 
significant. 
Thus looking for presence of MS alone helps predicting future 
development of CVD and diabetes. Thus we recommend the use of IDF 
criteria than conventional criteria to know the probable burden of 
cardiovascular risk in the community through the means of MS which can 
predict future development of CAD and DM and thereby helps 
professional organisations and the public to implement primary 
prevention strategies as early as possible in the form of exercise, anti-
atherogenic diet, life style and behavioural modifications260. 
Though the type of coronary vessel involved viz., single vessel 
disease/ double vessel disease/ triple vessel disease is not significant here 
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with the p value of 0.335, 0.605, 0.066 respectively, the prevalence of 
Triple vessel disease is more common in MS than non MS group. 
It is clear from the study that MS strongly predicts coronary artery 
disease and cardiovascular disease mortality than its individual 
components261. 
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RECOMMENDATIONS 
• In the Indian set up use of IDF consensus definition is the ideal one to 
diagnose MS and for risk stratification.  
• In order to reduce the risk of cardiovascular disease morbidity and 
mortality, the need to assess for other components of MS when any one is 
detected should be emphasised to all health care professionals. 
• Regular physical activity and healthy diet should be emphasised among 
young individuals for primary prevention of CAD. 
• Awareness about the principal criterion (waist circumference) should be 
promoted and individuals to be encouraged to keep  tabs on it. 
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LIMITATIONS 
1. Those patients who met 4 out of 5 criteria for MS without the principal 
criteria (waist circumference more than 80 in women and more than 90 in 
men) were excluded from the MS group. 
2. Number of female patients involved in the study was low 
3. Due to time constraints the sample size had to be restricted. 
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CONCLUSION 
• In our study, 90 cases of acute MI aged ≤ 45 were studied for 
metabolic syndrome using IDF criteria. MS was diagnosed in 67 of 
90 cases studied. 
• Waist circumference was followed by Diabetes mellitus /Systemic 
hypertension/ elevated BP / hypertriglyceridemia/ elevated FBS 
and decrease in fasting HDL arranged in the order of prevalence in 
the study group which was statistically significant. 
• Among the 67 patients, 14 met all criteria for MS, 24subjects had 4 
and 29 subjects had 3 of 5 MS criteria, With WC ≥ 80 for females 
and ≥ 90 for males being a definite criterion. 
• The prevalence of alcohol, whether a smoker ,history of CAD in 
the family, dyslipidemia , and  vessel involvement – 
SVD/DVD/TVD were same for both MS and non MS group. 
• Thus it is obvious that MS predominates over other conventional 
criteria or scores in estimating the risk of developing MI and 
related complications and its prevalence in our study population is 
74.4% which is very significant.  
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• Though people living in low income countries like India have 
lower risk factor for CVD, compared with high income countries, 
the rate of death due to CVD is highest in low income countries. 
This is because there is better control of risk factor due to frequent 
use of proven drugs to reduce the risk of deaths. 
• Thus determinants like easy and timely access to health care and 
medicine, diagnosis of risk factor and treatment / control and 
greater awareness play an important role in preventing death.  
Hence the two means to counter the risk factors and decrease the 
mortality are health promotion and health care. 
• Health promotion component is to raise awareness and risk 
reduction. This is better done by identifying at risk individuals by 
the presence of MS component in this group and providing health 
care facilities for early detection and effective treatment in order to 
prevent cardiovascular disease morbidity and mortality. 
• From the study it is clear that IDF consensus definition for MS 
suits Indians best for identifying high risk individuals. Hence we 
recommend its use to help prevent CVD morbidity and mortality in 
younger individuals in whom it is difficult to estimate CVD risk. 
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• As the risk factors have an increasing trend in India so does the 
mortality. The cardiovascular crisis is waiting to worsen unless we 
improve the health care system.  
• Hence risk factor modification, regular physical activity and 
healthy diet among young patients should be emphasised for 
primary prevention of CAD. 
• The concept of metabolic syndrome is very important as it provides 
simple  and comprehensive information to the public.The medical 
professional should assess for presence of all the MS parameters 
whenever necessary. 
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PROFORMA 
Case NO.      :                                                                      
Name        :              
Age           :             
Sex              :     
IP. NO         :         
Occupation   : 
1. Chief Complaints: 
2. Past History:   Diabetes mellitus  
Hypertension 
IHD 
3. Family History:               Coronary Artery Disease                                         
                                            Diabetes mellitus 
                                            Hypertension 
4. Personal History:           Current smoking – Y/N 
                                            Alcohol consumption – Y/N 
5. Blood Pressure 
6. Waist Circumference   
7. FBS                                                                                                                                
8. Triglycerides  
9. HDL – C  
10. Cardiac Enzymes   
11. ECG 
12. Echo  
13. Coronary Angiogram 
                              CONSENT FORM 
                                        
CONSENT FORM 
I, PSG Institute of Medical Science and Research, Coimbatore Institutional 
Human Ethics Committee 
INFORMED CONSENT FORMAT FOR STUDENT RESEARCH PROJECTS 
I / We (write name of the Student investigator(s) here) S.varun  Post graduate 
M.D (General Medicine), 2012 batch (course and year of admission, batch [Regular 
or Additional]) students of the PSG Institute of Medical Sciences & Research (PSG 
IMS&R), am / are carrying out a study on the topic:  
A STUDY ON  PREVALENCE OF METABOLIC SYNDROME IN 
PREMATURE CORONARY ARTERY DISEASE PROVEN BY CORONARY 
ANGIOGRAM as part of my / our student research project being carried out under 
the aegis of the Department of General  Medicine.   
My /Our research guide is Dr.SUJAYA MENON ; Designation: Professor, 
Department of General Medicine, My co- guide is Dr. G. Rajendiran Professor, HOD, 
Department of Cardiology PSG IMSR. 
The justification for this study is Though studies have revealed that the 
presence of metabolic syndrome constitutes around 6 fold increase in the cardio 
vascular mortality, the levels of increased risk have not been clearly defined that too 
in younger age group. The increased risk of morbidity and mortality associated with 
metabolic syndrome makes it essential in understanding the dimension of this 
syndrome for allocation of health care and research resources and for other purposes 
.These traditional risk factors all together accounts for approximately half of the risk 
of  first myocardial infarction, especially in the Asian Indian population. However 
both incident and prevalence of CVD will likely to increase in the next decades with 
significant socio-economic consequences ,very few studies have reported on the 
prevalence of metabolic syndrome in the native Indian population based on 
epidemiological studies and almost no studies been conducted on its prevalence in 
younger age group .This is particularly relevant as india has the maximum number of 
diabetes patients , hence early intervention of this metabolic syndrome with intensive 
lifestyle modifications in the form of diet, exercises and drugs would definitely 
prevent future development of CVD like myocardial infarction and this study will 
definitely helpful in establishing primary prevention strategies. 
The aim of this study is: 
To evaluate the prevalence of metabolic syndrome in premature coronary 
artery disease proven by coronary angiogram using IDF criteria. 
Sample size: 90  patients. 
Respondents are (population group & .age group): patients who have been diagnosed 
as premature coronary artery disease     . 
Location: PSG IMSR. 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out (strike off items that are not applicable):  
Initial interview (specify approximate duration): 20 minutes.  
Health education sessions: Number of sessions- ONE. 
Approximate duration of each session: 10 minutes.  
Clinical examination (Specify details and purpose): YES. General and system wise 
examination as a part of routine work up. 
Blood sample collection: Specify quantity of blood being drawn:~5ml 
Purpose- To estimate fasting TGL,HDL & Blood sugar.Discomfort- Minimal pain 
while drawing blood sample. 
Medication given, if any, duration, side effects, purpose, benefits: NIL 
Final interview (specify approximate duration):NIL  
If photograph is taken, purpose: NO 
 
Benefits from this study, if any: .Helps us to know the present status of distribution 
of metabolic syndrome among premature coronary artery disease population and 
make us plan early primary prevention strategies towards at risk population in 
preventing complications. 
How the results will be used: Study will be submitted to "The Tamil Nadu DR. 
M.G.R Medical University" as a part of PG thesis.  
If you are uncomfortable in answering any of our questions during the course 
of the interview / biological sample collection, you have the right to withdraw from 
the interview / study at anytime. You have the freedom to withdraw from the study 
at any point of time. Kindly be assured that your refusal to participate or withdrawal 
at any stage, if you so decide, will not result in any form of compromise or 
discrimination in the services offered. You will continue to have access to the regular 
services offered to a patient. You will NOT be paid any remuneration for the time you 
spend with us for this interview / study. The information provided by you will be kept 
in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used 
for approved research purposes only.  
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the student investigators from the PSG IMS&R. 
Having understood the same, I hereby give my consent to them to interview me. I 
affixing my signature / left thumb impression to indicate my consent and willingness 
to cooperate in this study.  
 
Respondent ID: _________.    
Signature / Left thumb impression of the Respondent.   
Signature of the Interviewer with date 
IHEC CONTACT NUMBER: 0422 2570170, Extn-5818 
 
ABBREVIATIONS 
ACS  -  Acute Coronary Syndrome 
ADA  -  American Diabetes Association 
ACC  - American College of Cardiology 
BMI   - Body Mass Index 
CAD  -  Coronary Artery Disease 
CRP  - C Reactive Protein 
CVD  -          Cardio Vascular Disease 
CURES -         Chennai Urban Rural Epidemiology Study 
DECODE -     Diabetes Epidemiology:Collaborative  analysis Of    
  Diagnostic criteria in Europe 
ESC  - European Society of Cardiology 
FRS   - Framingham Risk Score 
ID  - Implantable Defibrillator 
IRS  -         Insulin Response Syndrome 
IDF  -         International Diabetes Federation         
LVD  - Left Ventricular Dysfunction 
METS/MS -       Metabolic Syndrome 
 MI     - Myocardial Infarction                        
NSTEMI -  Non ST Segment Elevation MI              
NHLBI - National Heart Lung And Blood Institute     
PAR  - Population Attributable Risk 
PAI 1  - Platelet Adhesion Inhibition 1 
PCI   -   Precutaneous Coronary Intervention 
RCA  -  Right Coronary Artery 
SERCA 2a -         Sarcoplasmic Reticulum Ca2+ Atpase     
SHT  -         Systemic Hyper Tension 
SNP   - Single Nucleotide Polymorphisim 
SAVE  -  Survival And Ventricular Enlargement 
UKDAS -  United Kingdom Asian Diabetic Study  
 WHO  -      World Health Organisation 
 WC    -  Waist Circumference 
WHR  -  Waist Hip Ratio 
 
 
 
 
 
 
 
 
 
